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SUMMARY 
 
Buruli ulcer is an infectious disease caused by an environmental pathogen, Mycobacterium 
ulcerans, which is the third major mycobacterial pathogen of man, after M. tuberculosis and 
M. leprae. Since 1980, dramatic increases in the incidence of Buruli ulcer have been reported 
from West African countries, sometimes associated with man-made environmental changes. 
After the first international conference on Buruli ulcer in 1998 (Yamoussoukro meeting), 
attention has been drawn to the severity of this neglected disease and to its many poorly 
understood features. Since then new initiatives have been undertaken to promote control and 
research efforts. Within the framework of WHO identified research priorities, the present PhD 
project focused on the development of new molecular genetic tools to investigate M. ulcerans 
epidemiology and pathology.    
Apart from the association of Buruli ulcer with swampy environments, little is known about 
risk factors, environmental reservoirs and pathways of transmission. One factor that impairs 
research on these issues is the lack of suitable fine typing methods to track different M. 
ulcerans subclones and their spreading within a community. The comprehension of the 
population structure itself and of the mechanisms leading to genetic variability also suffers 
from this lack of tools. For this reason, we developed a new plasmid-based microarray 
approach, which was used to perform a comparative genomic analysis of 30 M. ulcerans 
strains, from different geographical origins.  Fifteen large sequence polymorphisms were 
identified affecting genes of all major functional categories. Results obtained with this 
prototype microarray demonstrated that insertional/deletional events, often associated with 
insertion sequences are the most important mechanisms of genetic diversification in M. 
ulcerans. Analysis of strain diversity with a larger microarray should represent a suitable tool 
for micro-epidemiological studies.  
Within the framework of a Buruli ulcer survey in Cameroon, an optimized diagnostic PCR 
was developed. The method, operating on genetic material extracted directly from swab 
samples, demonstrated the usefulness of such highly sensitive technique for epidemiological 
studies. Neglected Buruli ulcer foci have been rediscovered and an association between Buruli 
ulcer cases and slow flowing water basins have been reconfirmed. 
A quantitative PCR specific for M. ulcerans DNA, the IS2404 real-time PCR, was developed 
with the aim to gain insights into the pathology of the disease. The very high sensitivity and 
specificity of the method allowed the quantitative assessment of the dissemination of the 
mycobacteria in Buruli ulcer lesions, and its comparison with histopathological changes. 
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Although the heaviest mycobacterial burden was detected in the central foci of the lesions, we 
could measure significant amounts of mycobacterial DNA and microcolonies in samples from 
peripheral regions and occasionally in healthy appearing excised tissue margins. Additional 
peaks of mycobacterial DNA clearly marked sites where satellite lesions were developing. 
Even when granulomas provided evidence for the development of cell-mediated immunity, 
development of satellite lesions by contiguous spreading was not completely prevented. The 
technique offers also the potential to predict recurrences: in one case we could demonstrate 
that a relatively small number of mycobacteria that have spread into healthy appearing tissue 
can lead to the development of a recrudescence. These data altogether support the concept that 
wider surgical excision improves the chance of healing of Buruli ulcer. The application of our 
approach for assessing the mycobacterial burden in excision margins, combined with long 
term follow-up of patients, should help to improve current guidelines for surgical treatment of 
Buruli ulcer.  
It is becoming more and more evident that mycobacterial spreading can occur even at distant 
sites from the original primary ulcer, producing so called “metastatic lesions”. The 
contribution of re-activation versus re-infection is not clear, neither is the mode of spreading 
into the body known. In the case of a HIV+ patient, we could report the insurgence of 
multifocal aggressive lesions leading to osteomyelitis. The time span interposing between the 
primary Buruli manifestations and the recurrence at the new sites, together with the physical 
distance of the patient from the endemic area, is such to argue about eventual persistence of 
M. ulcerans in an immunocompromised individual. 
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ZUSAMMENFASSUNG 
 
Buruli Ulkus, eine Infektionskrankheit verursacht durch Mycobacterium ulcerans, ist nach 
Tuberkulose und Lepra die dritt häufigste durch Mykobakterien verursachte Erkrankung. Seit 
1980 ist die Inzidenz von Buruli Ulkus in ostafrikanischen Ländern dramatisch angestiegen. 
In einigen Fällen ist dies mit durch den Menschen hervorgerufenen Veränderungen der 
Umwelt assoziiert. Die erste internationale Konferenz über Buruli Ulkus im Jahre 1998 
(Yamoussoukro Konferenz) richtete erstmals die Aufmerksamkeit auf die Schwere und die 
wenig verstandenen Mechanismen dieser bis dato weitgehend unbeachteten Erkrankung. 
Innerhalb der von der WHO ausgerufenen Forschungsschwerpunkte versucht diese 
Doktorarbeit durch Entwicklung molekular genetischer Methoden dazu beizutragen, die 
Epidemiologie und Pathologie der M. ulcerans Infektionen zu klären. 
Bis auf die Verbindung des Auftretens von Buruli Ulkus mit Feuchtgebieten ist über 
Risikofaktoren, Umweltreservoir und Übertragungswege wenig bekannt. Ein wichtiger 
Faktor, der die Klärung dieser Fragen erschwert, ist das Fehlen geeigneter 
Typisierungsmethoden um M. ulcerans Subklone zu unterscheiden und so die Ausbreitung 
der Erreger innerhalb eines endemischen Gebietes zu verfolgen. Das Verständnis der 
Populationsstruktur der Mycobakterien und der Mechanismen die zu genetischer Variabilität 
des Erregers führen, ist hiervon ebenso betroffen. Um diese Fragen zu klären, haben wir einen 
DNA Mikroarray entwickelt, auf dem Plasmide immobilisiert wurden, die genomische 
Sequenzen des Erregers enthalten. Dieser Prototyp wurde benutzt, um eine vergleichende 
genomische Analyse von 30 M. ulcerans Stämmen unterschiedlicher geographischer Herkunft 
durchzuführen. Es wurden 15 große Sequenz- Polymorphismen identifiziert, die Gene aller 
wichtigen funktionellen Kategorien umfassten. Diese Ergebnisse zeigten, dass das Auftreten 
von Deletionen, häufig assoziiert mit der Insertion von Sequenzen, der wichtigste 
Mechanismus der genetischen Diversifikation von M. ulcerans darstellt. Ein das ganze 
Genom von M. Ulcerans umfassender Mikroarray wird daher voraussichtlich detailliertere 
Analysen der genomischen Unterschiede zwischen Erregerstämmen und damit 
mikroepidemiologische Studien zur Ausbreitung genetischer Varianten des Erregers 
ermöglichen. 
Für eine Studie über die Verbreitung des Buruli Ulkus in Kamerun, wurde eine diagnostische 
Polymerase Kettenreaktion (PCR) optimiert. Die erfolgreiche Extraktion genetischen 
Materials aus Wundabstrichen gefolgt von der sensitiven PCR-basierten Detektion des 
Erregers bewies die Eignung dieser Technik für epidemiologische Studien. 
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1.1 History and epidemiology of Buruli ulcer 
 
Buruli ulcer is a disease of skin and soft tissue caused by an environmental pathogen, 
Mycobacterium ulcerans, which has the capacity to produce a damaging toxin.  The main 
burden of disease falls on children living in sub-saharan Africa but healthy people of all ages, 
races and socioeconomic classes are susceptible.   
M. ulcerans is the third most important mycobacterial pathogen of man, after M. tuberculosis 
and M. leprae1. The definitive description of M. ulcerans was published in 1948, when 
MacCallum and others reported 6 cases of an unusual skin infection in Australia, caused by a 
mycobacterium that could only be cultured in Löwenstein-Jensen medium when the 
incubation temperature was set lower than for M. tuberculosis2.  In Africa, large ulcers almost 
certainly caused by M. ulcerans had been described by Sir Robert Cook in 1897 and by 
Kleinschmidt in northeast Congo during the 1920s3. 
 
Prior to the 1980s, foci of M. ulcerans infection were reported in several countries in sub-
Saharan Africa including Congo, Uganda, Gabon, Nigeria, Cameroon and Ghana4. The 
Uganda Buruli Group coined the name "Buruli ulcer" because the cases they described were 
first detected in a Buruli county, near lake Kyoga5. 
Since 1980, dramatic increases in the incidence of Buruli ulcer have been reported from the 
West African countries of Benin, Côte d'Ivoire and Ghana. New foci were also discovered 
recently in Togo and Angola4 and older ones have been re-discovered in Cameroon6. 
Estimates vary, but there have probably been more than 30,000 cases in West Africa in the 
last 20 years. In southern Benin, a recent study has reported detection rates of 21.5/100,000 
per year, higher than for either tuberculosis or leprosy7. The same holds true for a national 
case search performed in Ghana in 1999, where the prevalence was estimated to be 
20.7/100,000, exceeding that of leprosy8. These figures do not show the complete picture as 
there is considerable under-reporting. Due to the focal distribution of the disease, Buruli ulcer 
represents the major health problem in some of the highly endemic areas of West Africa, for 
example in Côte d’Ivoire local prevalence of Buruli ulcer can be as high as 16.3%9, and in 
Ghana, in areas of high incidence, up to 22% of the population is affected 10. Several other 
countries outside Africa are also endemic including rural areas of Papua New Guinea, 
Malaysia, French Guyana and Mexico. In Australia, the disease remains uncommon but there 
have been increases in both the incidence and endemic areas in the last 10 years11,12.  
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Figure 1. Countries reporting Buruli ulcer (Source: Johnson et al, PLoS Med. 2005) 
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1.2 Causative organism and toxin secretion 
 
M. ulcerans belongs to a group of mycobacteria that are potentially pathogenic for humans 
and animals. These are sometimes called “opportunistic mycobacteria” or “occasional 
pathogens”. Most species belonging to this group are found widespread in the environment 
and may become pathogenic under special circumstances13. 
M. ulcerans is a slow growing mycobacterium. Its generation time is about 20 hours and 
primary cultures may take between 6 and 8 weeks to be positive3. Incubation at about 32ºC is 
essential for its isolation in primary culture14. Another important factor is the oxygen 
concentration. Reduced oxygen concentration enhances the growth of M. ulcerans, suggesting 
a preference of this organism for microaerophilic environments15. 
M. ulcerans is unique among mycobacteria in that much of the pathology appears to be 
mediated by production of toxic macrolides, the mycolactones that are required for 
virulence16. These soluble toxins have immunosuppressive and cytotoxic properties in-vitro 
and can be isolated from the culture filtrate of the mycobacterium. When injected into healthy 
guinea pigs, histopathological changes compatible to Buruli ulcer lesions, were induced17. 
Mycolactones induce cell death by apoptosis, which may explain the absence of an 
inflammatory immune response despite the extensive tissue damage18. 
In contrast to the wild type M. ulcerans, mycolactone negative mutants fail to colonize the 
salivary glands of water insects, suggesting that these molecules may play a role in the ability 
of M. ulcerans to colonize reservoir species16,19. 
Until now no cell receptor has been found to explain the cascade of effects induced by 
mycolactones20. 
 
 
 
 
Figure 2.  Mycolactone core structure: 12-membered ring to which two polyketide-derived 
side chains (R1 and R2) are attached. (Source: George et al, Science 1999) 
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1.3 Pathogenesis  
 
1.3.1 Clinical forms 
Clinically M. ulcerans disease manifests as papules, nodules, plaques, oedematous forms and 
ulcers. The disease may be active (ongoing infection) or inactive (previous infection with 
characteristic depressed stellate scars with or without sequelae). Any part of the body can be 
affected but it mostly occurs on limbs.   
Early Buruli lesions may initially appear as a mobile subcutaneous nodule, a papule or a 
raised plaque14.  A subgroup of patients presents with rapidly progressive oedema of a whole 
limb, abdominal wall or side of face without an obvious focal lesion.  Part or all of the 
affected area will subsequently ulcerate. Recent anecdotal reports suggest that timely 
antibiotic therapy may greatly reduce the resulting necrosis. 
Ulceration can be extensive and disfiguring, often affecting 50% or more of a limb. Patients 
usually present to hospital when large ulcers are established, or when secondary infections 
cause new symptoms of pain and fever.  Sometimes, in advanced lesions, the infection 
spreads beyond the deep fascia, affecting the bone21. In Benin it has estimated that up to 10% 
of the patients have severe osteomyelitis22. Some lesions may arise from haematogenous 
spread23, 24. Contractures are common and up to 10% of cases admitted to a hospital require 
amputation of a limb. Lesions close to the eyes may lead to blindness. 
 
1.3.2 Histopathology 
Progressive M. ulcerans infection causes characteristic tissue changes. Initially there is 
coagulative necrosis of the lower dermis and subcutaneous fat. The organisms are present in 
clumps or in smaller microcolonies in the centre of the lesion. In these early lesions there is 
little or no evidence of an inflammatory response or the development of granulomas. As the 
disease progresses all elements of the skin are affected including nerves and blood vessels. 
Healing is associated with the formation of granulation tissue at the edges of the ulcer. In this 
stage the number of bacilli decreases and granulomas containing epithelioid cells and 
Langherans giant cells may be seen25.  
Histological specimens typically show large clumps of extracellular acid fast organisms 
surrounded by areas of necrosis and a poor or absent inflammatory response26. Subcutaneous 
fat is particularly affected, but underlying bone may also become involved in advanced cases3. 
Later in the natural history of the disease the immunosuppressive effect of the toxin is 
somehow overcome by the host: cell mediated immunity develops and healing commences1. 
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It is possible that macrophages may initially engulf the organism after entry trough the skin, 
an accumulation of toxin may sequentially cause lysis of the macrophages and paralysis of the 
functions of infiltrating lymphocytes or macrophages. In turn, this localized 
immunosuppression may contribute to a delay in an early systemic immune response to 
mycobacterial antigens. This may account for the observation that patients with active lesions 
are often unresponsive to M. ulcerans-derived antigen (burulin) on skin testing27. Later, 
during the healing phase, characterized by the appearance of granulomas, there is conversion 
to a positive burulin test indicating that a specific cellular response develops.  
 
 
 
 
    
          
      
 
 
Figure 3. Clinical forms of Buruli ulcer                Figure 4. BU Histology 
a:  nodule; b: early ulcer; c: late ulcer; d: crippling    a: ZN staining 
deformity after self-healing      b: Buruli type fat necrosis 
(Source: Asiedu et al, WHO 2000) 
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1.4 Diagnosis 
 
Early treatment of M. ulcerans disease provides a better outcome than treatment of the 
ulcerative forms, but it is often impaired by the difficulties of diagnosis. In a known endemic 
area, an experienced person can diagnose an advanced M. ulcerans infection on clinical 
grounds. The commonly used diagnostic laboratory tests are: i) detection of mycobacteria by 
Zihel-Neelsen (ZN) staining, a technique that lacks sensitivity and specificity, ii) culture of M. 
ulcerans, which may take several months, iii) detection of characteristic histopathological 
changes in excised tissue and iv) detection of M. ulcerans DNA by PCR, representing a rapid, 
sensitive and specific diagnostic method14. 
 
1.4.1 PCR approaches 
The application of PCR approaches as diagnostic test constitutes a big improvement: the 
repetitive element 2404 (IS2404), an insertion sequence present in multiple copies in the M. 
ulcerans genome, is used as DNA target and it guarantees the superior sensitivity and 
specificity of the method.  
The PCR diagnosis permits the confirmation of the clinical diagnosis in a short time, as long 
as high laboratory standards are ensured to avoid the risk of contamination and consequent 
false positive results. Because of the inherent fragility of this technique, improvements and 
optimization of PCRs protocols have been made to allow the use of starting material obtained 
through non-invasive sampling approaches (like swab samples). 
PCR applications to environmental samples demonstrated for the first time the presence of M. 
ulcerans in the environment28, when it became clear its nature as ubiquitous 
mycobacterium29,30,31,32. After refinements of culture methods, in very few cases, it was also 
possible to isolate it and grow it33,19. Recent evidence indicates, however, that some other 
mycobacteria also harbour IS240434. 
In addition to this conventional diagnostic PCR, the recently developed real-time PCR method 
uses the TaqMan system (IS2404 TaqMan) to quantify M. ulcerans DNA by monitoring the 
real-time amplification of IS240435. This method offers the possibility to measure the starting 
amount of target DNA in clinical specimens and other samples, thus providing a measure of 
mycobacterial burden. Real-time PCR has several advantages over the conventional end-point 
PCR which include the reduction of risk of contamination, by eliminating the post-PCR 
processing and a diminished sensitivity to PCR inhibitors.  
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1.5 Treatment 
 
1.5.1 Surgical excision 
The mainstay of treatment is surgical excision of early lesions, which is often curative. 
Unfortunately many patients do not present until there is extensive and disfiguring ulceration, 
when there is no alternative but wide excision followed by skin-grafting, and sometimes even 
amputation21. Currently it is not clear how extensive surgeries should be performed and it is 
largely left to the individual judgment of the surgeon to find the right balance between an 
oversized excision and an incomplete removal of the pathogen, thus increasing the risk of 
recurrence. 
Observations at St. Martin’s Hospital, Agroyesum, in the Amansie west District of Ghana 
suggest that further surgery is needed for recurrent disease in more than 15% of cases and 
another study by Teelken et al. showed that relapse after surgery may occur in between 15-
47% of cases36.  
Untreated Buruli ulcer will eventually subside with the gradual development of host 
immunity.  However, by this time, tissue damage may be very extensive and scarring can lead 
to permanent functional and cosmetic deformity. Successful treatment will shorten the course 
of the disease and minimise deformity.  Skilled surgery, expert post-operative nursing care 
and restorative physiotherapy are required to achieve this.  The cost of those interventions 
may be beyond the means of local rural health services.  It has been estimated that the average 
cost to treat Buruli ulcer in Ghana is over 780 US dollars per person14,10. Even in Australia 
with access to universal health care, the cost and complexity of treating M. ulcerans infections 
can be considerable. 
 
1.5.2 Susceptibility to antibiotics 
M. ulcerans is susceptible to several antimycobacterial drugs in vitro but the only promising 
combination in the mouse footpad model was the combination of rifampicin and amikacin17. 
A human trial has recently shown that early nodular lesions may be rendered culture negative 
after a minimum of 4 weeks therapy with rifampicin plus streptomycin37. 
Further research to identify cheap, safe and effective oral drug combinations that can be used 
as an adjuvant to surgery or which could even replace surgery is urgently required.  
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1.6 Transmission 
 
The disease often occurs in people who live or work close to rivers and stagnant bodies of 
water. Changes in the environment, such as the construction of irrigation systems and dams, 
seem to have played a role in the resurgence of the disease. For instance, in the Busoga 
district in Uganda, Barker postulated that the outbreak was related to unprecedented flooding 
as a result of heavy rainfall38. In Nigeria, infections have emerged when a small stream was 
dammed to make an artificial lake39.  
In Phillip Island, Australia, a recent outbreak of the disease was temporally associated with 
the formation of a small swamp that, after its improved drainage, was followed by a cessation 
of cases12. 
Although the transmission of Buruli ulcer is not clearly explained, there is some mounting 
evidence for an association of focal outbreaks with flooding, human migration38 and man-
made topographical modifications such as dams and resorts. Deforestation and increased basic 
agricultural activities may have also significantly contributed, especially in West Africa, 
where the disease is rapidly emerging. 
Trauma is probably the most frequent means by which M. ulcerans is introduced into the skin 
from environmental sources. The initial trauma can be as slight as a hypodermic needle 
puncture or as severe as a gunshot40.  Epidemiological data has not spoken for frequent 
person-to person transmission41. 
In a study from Cote d’Ivoire9, the wearing of long trousers was a protective factor against 
Buruli ulcer in communities with a high prevalence of the disease.  In another study in Ghana, 
of 96 patients with M. ulcerans infection there was a significant association between lesion 
and occupational exposure42. 
M. ulcerans was first detected in the environment in the 1990s by Australian researchers using 
polymerase chain reaction (PCR)43,44. Subsequently, PCR was used by others to detect M. 
ulcerans in aquatic insects obtained from endemic areas in Africa, leading to the hypothesis 
that M. ulcerans may be transmitted by biting water bugs of the insect order Hemiptera. In 
support of this proposal, M. ulcerans has been detected in the salivary glands of Naucoris spp. 
(Naucoridae), and has been transmitted to laboratory mice via these aquatic insects19. There is 
additional evidence that M. ulcerans DNA can be detected by PCR in other aquatic insect 
predators (e.g., Odonata, Coleoptera), as well as in aquatic snails, small fish, and the biofilm 
of aquatic plants45,30. Despite this, only two pure cultures of M. ulcerans have been obtained 
from environmental sources46,19. In Australia, it has been postulated that aerosols arising from 
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contaminated water may disseminate M. ulcerans and infect humans via the respiratory tract, 
or through contamination of skin lesions and minor abrasions, but this has yet to be proven47. 
Recent progress has been rapid, but the exact mode of transmission and the key environmental 
reservoirs remain to be elucidated.  
 
 
 
 
Figure 4. Semi-Aquatic Hemiptera positive for M. ulcerans 
(Source: Johnson et al, PLoS Med. 2005) 
 
1.7 Immune response 
 
M. ulcerans is unique among mycobateria, not just for its toxin production, but also because 
the pathogen multiplies extracellularly in the host and there is little inflammatory response. 
It is likely that soon after infection, mycolactone production prevents a local immune 
response48. Nevertheless, human lesions do heal spontaneously. The histological appearance 
of late lesions is similar to other mycobacterial disease, with small numbers of organisms and 
granuloma formation (contrasting with the large clumps of bacilli in early lesions). In a late 
stage of infection, T cells become reactive as evidenced by the human delayed 
hypersensitivity response to burulin27. Other evidence exists for the protective role of acquired 
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cellular immunity: bacillus Calmette-Guèrin vaccination is protective in mice against low-
dose inoculation49 and to some extent in man50. Finally, data from Benin suggest that there is 
a second peak of incidence in the elderly, which may correspond with declining immunity51. 
Interestingly, patients with a past history of M. ulcerans infection typically have a strong Th-2 
cytokine response when their lymphocytes are exposed in vitro to M. ulcerans.  In one 
fascinating case study, the development of ulcerative M. ulcerans disease was associated with 
a switch from the Th-1 to Th-2 phenotype52. 
Antibody responses may also play a protective role, but this is difficult to study because of the 
strong overlap between different species of mycobacteria.  
 Another observation is noteworthy: if the progress of the disease is determined by the ability 
of the host to mount a cell mediated immunoresponse, it would be expected that HIV co-
infection would influence its course, but this does not appear to be the case. Anecdotal 
evidence from observations on families in endemic areas raises the possibility that host factors 
influence susceptibility to M. ulcerans infection53,54. 
There is no specific vaccine against M. ulcerans available, but M. bovis - BCG offers some 
protection, albeit short lived54,50.  BCG may also provide more enduring protection against the 
most severe forms of Buruli55.  
Current prospects for better vaccines include improved or repeated BCG vaccination, rational 
attenuation of a M. ulcerans isolate and subunit vaccines, aimed at immunodominant protein 
antigens or the toxin itself56. 
 
1.8 Genome and bacterial population structure 
 
Mycobacteria are known to have a very limited genomic diversity, which makes it particularly 
difficult to develop finger printing methods for microepidemiological studies. M. tuberculosis 
complex is constituted by 5 different members (M. tuberculosis, M. africanum, M. microti, M. 
bovis, M. canetti) which share a high genomic similarity, even though specialized in infecting 
different hosts. M. ulcerans DNA is closely related (99.6% identity) to another 
mycobacterium species, M. marinum, from which it could have recently diverged by the 
acquisition and concomitant loss of DNA, in a manner analogous to the emergence of M. 
tuberculosis, where species diversity is being driven mainly by the activity of mobile DNA 
element57. Hallmark is the acquisition of the virulence plasmid58. Several conventional and 
newly developed typing techniques have attempted to describe the population structure of M. 
ulcerans and to investigate its evolution. 
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Multilocus Sequence Typing (MLST). This technique compares the sequences of 
housekeeping genes derived from different isolates. The application of this method on 18 
different M. ulcerans strains resulted in the identification of 6 genotypes related to the 6 
geographical areas of Suriname, Mexico, China/Japan, Africa and Victoria (Australia). 
Comparative analysis between M. marinum and M. ulcerans confirmed their relatedness, 
suggesting a recent divergence of M. ulcerans, by the acquisition and concomitant loss of 
DNA, like the specific insertions sequences IS2404 and IS260657. 
16S rRNA sequencing. This method employs the sequencing of 16S rRNA genes, which have 
changed little over millions of years as organisms evolved. The slight changes that have 
occurred provide clues as to how closely or distantly various organisms are related. This 
technique revealed identical signature sequences in M. marinum and M. ulcerans59,60: the only 
sequence differences within this locus are two nucleotides at the 3’ end of the gene, which 
varies only in certain M. ulcerans strains61,62. 
Amplified Fragment Length Polymorphism (AFLP). This technique is based on digestion of 
whole-genomic DNA with two endonucleases, ligation of double stranded oligonucleotide 
adaptors to the restriction halfsites and selective amplification of the modified restriction 
fragments with adapter specific primers. Starting from 12 M. ulcerans strains from Australia, 
Malaysia and Africa, it could discriminate just two groups of isolates: the African group and 
the Australian (and Malaysian) group63. 
PCR-restriction Profile Analysis (PRPA). This method involves an amplification step of the 
3’ 16S rRNA and the subsequent cutting with three restriction enzymes. The M. ulcerans 
strains tested were split into three categories: African, Australian and Mexican33.  
Restriction Fragment Length Polymorphism (RFLP). The basis of this technique is to identify 
the number of a particular repeated element (like IS2404) and its own distinctive loci, by 
cutting the whole genome with different restriction enzymes and then probing it with the 
chemically labelled element. The attempt to differentiate 14 M. ulcerans isolated by using 
IS2404 as probe, led to the identification of 6 groups belonging to Africa, Australia, South 
Asia, Asia, South America and Mexico, respectively46. 
When a polymorphic GC-rich repeat sequence was used as probe, it was possible to 
characterize 11 distinct RFLP types, distinguishing even strains from Benin and Zaire64. 
2426 PCR. This technique is based on the amplification of DNA between the insertion 
sequences (IS2404 and IS2406), using outward-directed primers specific for such ISs. It 
allowed the identification of 9 distinctive profiles correlating with the geographical areas. 
Within each group there was lack of genotype variation44. 
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Combination of IS2404 PCR and GC-rich repeated sequence. This method uses the outward-
directed IS2404 specific primers in combination with an oligonucleotide targeting the GC-rich 
repeated motif. Comparison of banding profiles revealed 10 different patterns corresponding 
to the geographical origin of the isolates. The technique described above confirmed the clonal 
population structure of M. ulcerans within a given area and an overall remarkable genomic 
architecture homology65. 
Pulsed Field Gel electrophoresis. This technique, based on the migration of large DNA 
fragments in an electric field, employs the principle that large DNA fragments require more 
time to reverse than do small DNA fragments. By alternating the direction of the current 
during gel electrophoresis, it is possible to resolve DNA fragments of 100 -1,000 kb. This 
approach was used to compare genome sizes of M. marinum versus M. ulcerans and it showed 
shrinkage of the M. ulcerans genome by 200 kb57.  
When undigested M. ulcerans DNA was used, a band of about 174 kb was detected, 
corresponding to a circular plasmid (pMUM001) which comprises 81 protein-coding 
sequences. The primary function of such plasmid is mycolactone toxin production66. 
The occurrence of inter-strain variability was also discovered at the plasmid level, both 
related to the mycolactone structure that can be produced by different isolates16 and related to 
frequent genetic rearrangements that render the virulence plasmid particularly unstable67. 
MIRU-VNTR. Mycobacterial interspersed repetitive units are 46 to 100 bp long sequences 
that are interspersed in different copy numbers throughout the genome. The method is 
routinely used for the genotyping of M. tuberculosis: the amplification of such loci with 
primer specific oligos produce amplicons whose size can be used to estimate the number of 
repeats at each locus. A combination of 4 MIRU loci on 39 M. ulcerans strains identified 
seven different profiles largely grouped according to their geographical origins. Once again, 
all the African isolates produced a single profile68, 65. 
 
All the above mentioned typing methods proved a limited discriminatory power, particularly 
insufficient to differentiate among isolates from the same area. This makes them unsuitable to 
perform micro-epidemiological studies, where the fingerprinting of the strains is aimed at 
revealing transmission pathways and environmental reservoirs. Whole genome analysis, 
allowing genome-wide comparisons, might represent the best approach to deal with this issue. 
There is urgent need for innovative techniques able to attempt this type of investigation. New 
opportunities will come from the publication of the whole M. ulcerans genome sequence in 
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2005. Microarray analysis of genomic DNA is one of such methods that could prove 
extremely helpful to discriminate M. ulcerans variants. 
 
Microarray analysis 
The ability to immobilize thousands of DNA fragments on a surface, such as a coated glass 
slide or a membrane, has led to the development of DNA microarray technology. The two 
common applications of DNA microarray technology in microbiology are the exploration of 
genome-wide transcriptional profiles and the measurement of the similarities or differences in 
genetic contents among different microbes. In this context microarray could probably be 
suitable to distinguish the highly homogeneous M. ulcerans population, to perform micro-
epidemiological studies.  
In the case of M. tuberculosis complex this approach has led to the identification of large 
sequence polymorphisms (LSP) that allowed the distinction between M. bovis BCG and M. 
tuberculosis, through the identification of at least 18 regions of diversity (RD1 to RD18)69, 70. 
The construction of a microarray allowed detection of small-scale genomic deletions among 
19 clinically and epidemiologically well-characterized isolates of M. tuberculosis71, showing 
that the deletions are likely to contain ancestral genes whose functions are no longer essential 
for the organism's survival, whereas genes that are never deleted constitute the minimal 
mycobacterial genome. These examples demonstrated that array-based comparative genomics 
constitutes a promising approach to exploring molecular epidemiology, microbial evolution, 
and pathogenesis of those species where deletion/insertion events account for most of the 
genomic variation, while single nucleotide polymorphism (SNP) rates are low.  
A major drawback to the implementation of microarray is the need to have a fully sequenced 
genome, before proceeding either with the oligos synthesis (in the case of oligos-based chips), 
or with the whole-genome primers design (in the case of PCR fragment-based chips).  
Shotgun DNA microarrays may overcome this problem, by offering the possibility for 
genome-scale experiments, even in the absence of a complete genomic sequence72. However, 
they do not overcome the laborious and time consuming preparation of PCR fragments 
suitable for spotting, which often constitutes the bottleneck of the technique.  
The development of a plasmid-based microarray can circumvent both the need for a 
completely sequenced genome and for the generation of PCR fragments.   
 
 
 
 CHAPTER 1. Introduction 15 
1.9 Research framework on Buruli ucer 
 
Buruli ulcer is mainly a disease of poor people, living in remote rural communities with little 
economic or political influence. This has hampered recognition of Buruli ulcer as major 
problem: national surveillance systems did not pick up the appearance of new outbreaks and 
affected populations often believe that there is no medical treatment, which discourages them 
from seeking help73,74.  
On the other hand, the absence of a potential first-world market has meant that there has been 
little private investment in drugs, diagnostics and vaccine development. Also research on 
Buruli ulcer was not very intense for a long time.  
A first step towards the recognition of the importance of BU was undertaken in December 
1997, when Dr Hiroshi Nakajima, then Director-General of the World Health Organization 
(WHO), announced that WHO would take the lead to mobilize the world's expertise and 
resources to fight the emergence of Buruli ulcer as a serious public health problem.  In 1998, 
WHO launched the Global Buruli Ulcer Initiative to coordinate control and research efforts, 
and organized the first International Conference on Buruli ulcer control and research in 
Yamoussoukro, Côte d’Ivoire (WHO Press Office, 1998, Fact Sheet No. 199). The resulting 
Yamoussoukro Declaration on Buruli ulcer drew attention to the severity of the disease and 
expressed concern about its many poorly understood features.  Five key aspects have been 
identified as most likely to provide immediate direct benefit to Buruli ulcer patients in the 
medium term: 
 
1. identification of the mode of transmission 
2. development of methods for early diagnosis 
3. improvement of treatment  
4. BCG trials and development of new vaccines 
5. cultural and socio-economic studies 
 
It is within such a framework of priorities that the present PhD project was developed, and it 
mainly focused on investigating the first three points, through the use of molecular and 
genetic tools. 
The field work and the accessibility to Buruli ulcer endemic areas constituted an important 
aspect of the work and the collaboration with the Amasaman Health Centre in the Ga district 
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of Ghana and with Aide aux Lepreux Emaus Suisse (A.L.E.S.) active in the Nyong river basin 
in Cameroon proved providential for the successful outcome of the project.  
In addition, the requirement for highly sophisticated DNA microarray technologies was met 
through collaboration with Prof. U. Certa (Hoffman La Roche, Basel), where part of the work 
to develop and implement new microepidemiological tools was undertaken. 
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2.1 Goal 
 
To contribute to the improvement of the health status of patients affected by Buruli ulcer, by 
expanding basic knowledge on the disease. 
 
2.2. Objectives 
1. To develop a microarray to study the basis of the genetic variation of M. ulcerans, 
with the aim to obtain a new fine typing tool suitable for micro-epidemiological 
studies.  
2. To study the epidemiology of M. ulcerans in a rediscovered endemic area in 
Cameroon, thorough the implementation of a diagnostic PCR approach.  
3. To develop a new real-time PCR to quantify M. ulcerans burden in tissues and 
environmental samples.  
4. To study mechanisms of pathogenesis and spreading of M. ulcerans in Buruli ulcer 
lesions to improve guidelines for the surgical procedure. 
5. To study the risk of recurrence in Buruli ulcer patients 
6. To evaluate the possibility of M. ulcerans reactivation versus reinfection.  
 
 
 
 
CHAPTER 3. Genetic diversity in M. ulcerans                                  27 
 
 
 
 
 
Detection of insertional/deletional genomic diversity in Mycobacterium 
ulcerans using a plasmid-based DNA microarray 
 
Simona Rondini1, Michael Kaeser1, Timothy Stinear2, Michel Tessier3, Cyrill Mangold3, 
Martin Naegeli1, Françoise Portaels4, Ulrich Certa3 and Gerd Pluschke1 
 
 
Swiss Tropical Institute, 4002 Basel, Switzerland1, Department of Microbiology, Monash 
University, Melbourne, Australia2 , F. Hoffmann-La Roche Ltd., Basel, Switzerland3, and 
Institute of Tropical Medicine,  Antwerp, Belgium4 
 
 
 
 
 
 
 
 
This article will be submitted in: 
Molecular Microbiology 
Chapter 3 
CHAPTER 3. Genetic diversity in M. ulcerans                                  28 
Abstract 
The analysis of genetic variability within natural populations of pathogens contributes to the 
understanding of genome function and evolution. In the case of Mycobacterium ulcerans, 
standard molecular typing methods such as multi-locus sequence typing, restriction fragment 
length polymorphism, and fingerprinting using variable number of tandem repeats have 
revealed a remarkable lack of genetic diversity and a clonal population structure within given 
geographical regions. Using a prototype plasmid-based microarray, with theoretical 15% 
genome coverage, we have initiated comparative genomic analysis of M. ulcerans. Fifteen 
large deletions comprising 1.8 kb to 53.1 kb were detected when 30 clinical isolates of diverse 
geographical origin were analysed. In many cases deletions were associated with the insertion 
of DNA sequences, thus representing InDel events. A total of 241 coding sequences that 
covered all major functional categories were found to be deleted in comparison to a reference 
isolate from Africa. Genes predicted to encode metabolic and information pathways as well as 
cell wall proteins were underrepresented, while pseudogenes, insertion sequence elements 
(ISE), unique hypothetical proteins and genes involved in detoxification-adaptation were 
overrepresented. Isolates coming from the same continent usually shared distinct large 
sequence polymorphisms. In some instances more than one type of deletion was observed for 
a given sequence region, suggesting recombination hot spots or selective advantage for loss of 
a particular region. Analysis of the sequences flanking deletions suggested that two highly 
abundant ISE (IS2404 and IS2406) are driving InDel variation. Given the significant strain 
variation uncovered by this small prototype microarray a larger genome-wide array may be a 
useful tool for micro-epidemiological studies.  
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Introduction 
The study of the genetic diversity within bacterial species has provided important information 
on aspects such as virulence1,2, antibiotic resistance3, epidemiology and microbial evolution4,5, 
6,7
. In the case of mycobacterial species, such as M. tuberculosis and M. ulcerans, very low 
intra-species diversity limits the use of genetic fingerprinting techniques that are based on 
sequence diversity in selected genetic elements. In other mycobacteria such as M. tuberculosis 
and BCG 8-11 genome-wide microarray analyses have led to the identification of large 
sequence polymorphisms. However, the complete genome sequence of an organism is 
required for the design of synthetic oligonucleotide or PCR product-based microarrays. When 
this information is not available, an alternative is a PCR product-based shotgun DNA 
microarray12. To avoid the laborious and time-consuming production of a large set of PCR 
products, we have developed a plasmid-based microarray. We have used this method for the 
differential genomic analysis of M. ulcerans, a human pathogen for which the fully assembled 
and annotated genome sequence is not yet available. 
 
M. ulcerans is the causative agent of Buruli ulcer (BU), an infectious disease characterized by 
chronic necrotizing skin ulcers13. BU is an emerging infectious disease particularly in West- 
African countries, but is also found in tropical and sub-tropical regions of Asia, the Western 
Pacific and Latin America14. Genetic analyses suggest the recent divergence of M. ulcerans 
from M. marinum, a well known fish pathogen, which can cause limited granulomatous skin 
infections in humans15. One of the hallmarks of the emergence of M. ulcerans as a more 
severe pathogen is the acquisition of a 174-kb plasmid bearing a cluster of genes necessary for 
the synthesis of the polyketide toxin mycolactone. This toxin appears largely responsible for 
the massive tissue destruction seen in BU16. The epidemiology and mode of transmission of 
M. ulcerans disease is not fully understood, partly because no molecular typing method is 
available that has sufficient high resolution for micro-epidemiological analyses. The apparent 
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lack of genetic diversity of M. ulcerans within individual geographical regions is indicative of 
a clonal population structure. The genotyping technique that has shown the highest 
discriminatory power so far is based on the use of outward-directed primers specific for the 
insertion sequence IS2404, in combination with an oligonucleotide targeting a repeated GC-
rich motif17. The application of this method allowed the resolution of 10 different M. ulcerans 
genotypes, corresponding to the geographic origin of the isolates. However, this level of 
resolution is not sufficient for micro-epidemiological analyses. We hypothesized that, as for 
M. tuberculosis18, deletional and insertional events mediated by repetitive sequence elements 
are the major mechanism for genomic variation in M. ulcerans. To test this hypothesis we 
developed a plasmid-based microarray and analysed genomic DNA from 30 M. ulcerans 
isolates of diverse origins. 
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Materials and Methods 
 
Plasmid-based DNA microarray 
Three hundred and fifty two E. coli plasmids  (pCDNA2.1 Invitrogen) were randomly 
selected from shotgun clone library, that was generated for the M. ulcerans genome project 
(http://genopole.pasteur.fr/Mulc/BuruList.html). Each plasmid contained a M. ulcerans DNA 
fragment from strain Agy-99 within the size range 2.3-2.7 kbp. Given a genome size of 5800 
kbp (T. Stinear, unpublished observations), this collection of 352 plasmids represents a 
theoretical coverage of approximately 15% of the Agy98 genome. Plasmid DNA was 
prepared using a Biomek 2000 Workstation. DNA yield was determined by measurement of 
optical density at 260nm using a GeneQuant spectrophotometer. Plasmids were dissolved at a 
concentration of 150ng/µl in 3xSSC buffer (20xSSC stock solution is 3M NaCl, 0.2M 
NaCitrate, pH 7.0)  
Using a Topspot spotter (Genescan), DNA was spotted onto glass slides (Superfrost) coated 
with poly-L-lysine and cleaned with nanopure water. The DNA samples, loaded on a piezo-
dispensing head containing 24 channels, were deposited by the robot device at identical 
locations on each of the slides. The resulting spots had an average diameter of 270µm, 
corresponding to a spotted volume of approximately 1nl and were 500µm apart when 
measured centre to centre. After spotting, the slides were incubated at 4ºC overnight, 
rehydrated under a controlled atmosphere with 50-60% humidity at room temperature (RT) 
for 1 hour and stored in the dark at RT until use. 
The layout of the spotted microarrays consisted of 2 replicates per field, each of them 
containing 32 controls and 352 plasmids. Two identical fields were printed on each glass 
slide, enabling the hybridization of two different probes on a single slide. Human Cot-1 DNA 
and plasmid DNA without insert served as negative controls. To assess DNA deposition on 
the microarrays, a 500bp DNA fragment comprising part of the Beta-lactamase gene present 
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in all plasmids was labelled with Cy3 and spotted. A biotinylated preparation of this fragment 
was used as another positive control.  
 
Preparation of biotinylated fragments of M. ulcerans genomic DNA for hybridization 
M. ulcerans strains used in this study are listed in Table 1. Bacterial pellets of about 60mg 
(wet weight) were heated for 1 hour at 95°C in 500µl of extraction buffer (50mM Tris-HCl, 
25mM EDTA, 5% monosodium glutamate). One hundred microliters of a 100mg/ml 
lysozyme solution were added. After 2 hours of incubation at 37°C, 70µl Proteinase K-10X 
buffer (100mM Tris-HCl, 50mM EDTA, 5% SDS, pH 7.8) and 10µl of a 20mg/ml proteinase 
K solution were added. After incubation at 45°C overnight, the samples were subjected to 
bead beater (Mikro-Dismembrator, Braun Biotech International) treatment with 300µl of 
0.1mm zirconia’s beads (BioSpec Products) at 3000 rpm for 7 minutes. Beads and undigested 
tissue fragments were removed by brief centrifugation and the supernatants were transferred 
to fresh tubes. An equal amount of phenol-chloroform (Fluka) was added and the DNA 
contained in the upper phase was precipitated with ethanol and resuspended in 150µl of water. 
The DNA yield was measured using a spectrophotometer (GeneQuant) and DNA quality (i.e. 
high molecular size and purity from RNA) was checked on a 1% agarose gel. 
Seven µg of M. ulcerans genomic DNA were digested with 3U of Sau3A1 (New England 
Biolabs) at 37ºC for 2 hours in a 60µl reaction volume. Efficiency of the digestion was 
controlled by analysing the size of the obtained DNA smear, which was between 100 and 
2000bp on a 1% agarose gel. The digested genomic DNA was purified by ethanol 
precipitation and biotinylated according to Pollack et al19 using a BioPrime kit (Gibco/BRL). 
Briefly, 2µg of DNA were mixed with 20µl of 2.5x random primer solution, brought to a final 
volume of 44µl with H2O and denatured for 5 min at 95ºC. Five µl of 10x dNTP mix (2mM 
dATP, dGTP and dTTP, 1mM dCTP and 1mM biotin-14-dCTP) were added on ice. One µl of 
Klenow fragment (40U/µl) was added, the total reaction volume being 50µl. After 2 hours of 
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incubation at 37ºC, the reaction was stopped by addition of 5µl stop buffer. The biotinylated 
DNA was purified using a Microcone YM-30 filter (Amicon/Millipore) and its concentration 
was measured by optical density at 260nm. 
 
Hybridization  
Five micrograms of biotinylated DNA were mixed with 30µg human Cot-1 DNA (1µg/µl, 
Roche Applied Science) and 100µg yeast tRNA (Gibco/BRL). The hybridization mix was 
concentrated to a final volume of 12µl using a Speed Vac Concentrator System. Prior to 
hybridization, 2.5µl of 20XSSC and 0.5µl of 10% SDS were added, the mix was denatured at 
95ºC for 3 min and subsequently incubated at 37ºC for 30min.  
Before use, the microarrays were cleaned with a N2 flow and exposed to UV in a Stratalinker 
2400 at 650X100µJ to fix the DNA on the chip. Immediately before application of the 
hybridization mix, the microarray was heated at 95ºC for 5 min. Subsequently it was placed in 
a hybridization chamber and 30µl of water were added at each end in the chamber to prevent 
dehydration of the hybridization mix. For each field of the array, 13µl of the hybridization 
mix was applied and a coverslip was placed on top. After hybridization at 65ºC for 16-20 
hours, the microarray was washed once with 2xSSC, 0.03%SDS for 5 min at 65ºC, twice with 
1xSSC for 5 min at RT and finally with 0.2xSSC for 5 min at room temperature. The 
coloration step was performed with 2ml staining solution containing 50% caseine, 1x maleic 
acid buffer (Roche Applied Science) and 2µg Streptavidin Cy3 Fluorolink (1µg/µl, 
Amersham) at RT for 30 min. Thereafter, the slide was washed twice for 5 min each with 1X 
TBS (0.15M NaCl, 0.02M Tris, pH 7.5) and 0.1 TBS. After drying with N2, the microarray 
was kept in the dark until scanning. 
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Scanning of microarrays and data analysis 
Images of the microarrays were acquired using a dual laser scanning microscope (GenePix 
4100A scanner; Axon Instruments Inc.) with an excitation wave length of 532nm and an 
emission wavelength of 570nm. Gain of the photomultiplier as well as parameters of contrast 
and brightness at which the image was viewed were kept constant for all measurements. The 
resulting acquired image was analyzed by the software GenePix Pro 4.1 (Axon Instrument 
Inc.), allowing the assignments of an average fluorescence intensity for each spot of the array. 
Both the images and the mean intensity values were used for data interpretation. 
Three types of hybridizations were carried out as quality control on the microarrays. A first 
hybridization with a Cy3-labeled random oligonucleotide (Microsynth) was performed to 
estimate the amount of spotted DNA. The 9mer oligonucleotides were diluted in a 
hybridization buffer containing 25% formamide, 5xSSC, 0.1% SDS, to a concentration of 
15pmol/µl. After 2 min of denaturation at 90ºC, 20µl of this solution were hybridized to a 
microarray for 5 min at RT. The microarray was then washed for 1 min with 2xSSC, 0.1% 
SDS and for 1 min with 0.05x SSC, dried with N2 and scanned. A second hybridization with 
the biotinylated β-lactamase gene fragment was carried out to specifically quantify the spotted 
plasmids. Four ng of biotinylated DNA were mixed with 30µg of human Cot-1 DNA (1µg/µl, 
Roche Applied Science) and 100µg yeast tRNA (Gibco/BRL) and the microarray was 
processed as already described above. A third hybridization served as a negative control and 
in this case no DNA was added to the hybridization mix.  
To select the spots of the microarray that yielded evaluable results, five hybridizations were 
performed using M. ulcerans Agy-99 genomic DNA. The 10 replicate values obtained for 
each spot served to select the spots to be included in the analysis of genomic diversity of M. 
ulcerans. All spots which yielded a signal lower than 2x the one given by the plasmid without 
insert (negative control) and all spots whose coefficient of variation was >30% were rejected. 
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232 spots with an average signal above the threshold and good signal stability were included 
in the subsequent comparative genomic hybridization analysis.  
 
Comparative genomic hybridization 
The DNA of 30 M. ulcerans strains was processed and hybridized under identical conditions. 
Hybridization were performed at least twice in order to obtain four sets of data. Spots 
associated with anomalies like dust particles or satellite spots due to the deposition of a 
second droplet of DNA material near the principal spot were rejected. For each plasmid the 
average signal value, standard deviation and coefficient of variation were calculated and a 
signal ratio in comparison to the reference strain was assessed. Outlier spots with a ratio 
higher than U2 (U2=Upper quartile+3x InterQuartile) were identified through a box plot 
analysis. 
 
Characterization of large sequence polymorphisms 
Microarray data indicating the presence of a deletion were verified by PCR analysis using 
primer pairs spanning the insert sequences of the respective plasmids and/or flanking regions. 
5’ and 3’ limits of reconfirmed genomic deletions with respect to the genome of strain Agy-99 
were determined by PCR analysis using multiple sets of primers complementary to flanking 
genomic regions. PCRs bridging the genomic breakpoints were performed using a long range 
PCR polymerase mix (Fermentas) according to the manufacturer’s description. PCR products 
were cloned into pGEM-T (Promega, Catalys AG) and sequenced using an ABI PRISM 310 
genetic sequence analyzer (Perkin-Elmer).  
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Results 
 
Comparative genomic hybridization of M. ulcerans isolates 
A microarray was constructed based on a random selection of 352 E. coli plasmids obtained 
from the shotgun library of the M. ulcerans genome project. Each plasmid contained a DNA 
fragment from the M. ulcerans strain Agy-99, a recent clinical isolate from Ghana. DNA 
hybridization signal intensities from 30 M. ulcerans clinical isolates were compared to those 
obtained with strain Agy-99. Box-plot analysis (Fig. 1) identified plasmids yielding outlier 
signals with respect to strain Agy-99. PCR analysis reconfirmed for 19 out of 20 of these 
plasmids an association of the outlier signal with a genomic deletion. Only one low 
hybridization signal represented a false positive result (refer p188 from strain 940511 Côte 
d’Ivoire, Fig. 1). The number of confirmed outlier plasmids per isolate ranged from zero in 
the case of most African isolates to nine for the isolates from Suriname and from French 
Guyana (Tab. 1).  
 
Three of the 19 plasmid inserts (p111, p299 and p341) that yielded reconfirmed outlier signals 
contained sequences from the virulence plasmid pMUM001 of M. ulcerans. Among the other 
16 plasmids derived from the M. ulcerans chromosome some contained fragments 
overlapping the same region (Fig. 2). Hybridizing regions were almost identical for p60 and 
p61. Both plasmids yielded outlier values with the isolates from Suriname and French 
Guyana. In the case of p88, p153 and p360, inserts were overlapping. A cluster of overlapping 
inserts were observed for p88, p153 and p360 and these produced outlier values for both of 
the Mexican isolates. The same pattern was seen with p291 and p124, which have inserts that 
are located in close proximity to each other in the genome (Fig. 2). These results from related 
inserts demonstrate the reproducibility of the differential hybridization analysis.   
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Characterization of genomic regions of difference  
The 5’ and 3’ limits of the genomic deletions with respect to the genome of strain Agy-99 
were determined by PCR analysis using multiple sets of primers complementary to plasmid 
inserts and to flanking genomic regions. The size of the deletions ranged from 1.8 kb to 53.1 
kb (Tab. 2). Some of the inserts were part of the same deletion (p124-p291, p60-p61 and p88-
p153-p360, respectively), so altogether 12 chromosomal regions of difference (RDs) were 
identified.  
In three of the 12 RDs (RD3, 9 and 12) two distinct types of overlapping but independent 
deletions (designated A and B) were observed. These deletions shared neither the 5’ nor the 3’ 
end sequences. The RD3 strains from Australia had a 3.5 kb deletion, while strains from 
Suriname and French Guyana had a slightly larger (3.8 kb) deletion. The RD9 isolates from 
Suriname and French Guyana had a larger (25.4 kb) deletion than the RD9 isolates from 
Japan and China (17.7 kb). The largest deletion (53.1 kb) was designated RD12 and was 
observed in strains from Japan and China. Isolates from Suriname and French Guyana had a 
significantly smaller RD12 deletion (35.2 kb). In RDs1, 2, 4, 7, 8, 10 and 11, deletions of 
identical size were observed in two isolates from the same geographical region. A 19.7 kb 
deletion in RD6 was found in isolates from two different geographical regions (Mexico and 
Japan/China, respectively).   
In order to assess whether polymorphisms undetected by the microarray analysis would 
frequently occur in the identified RDs, a detailed sequence analysis was performed in all M. 
ulcerans strains included in this study for two randomly selected RDs (RD5 and 12). Four 
distinct primer pairs were used to span the insert sequence plus 5’ and 3’ flanking sequence 
stretches.  In the case of RD12, the PCR analysis reconfirmed the presence of a deletion in the 
four strains presenting outlier signals in the microarray analysis, but no evidence for 
polymorphisms in the other strains was obtained. In the case of RD5, PCR analysis confirmed 
the presence of a deletion in the two Mexican strains with outlier signals (Fig. 3, lanes 28 and 
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29). Unexpectedly the analysis identified the presence of an insertion in strains from Japan, 
China, Suriname and French Guyana (Fig 3, tracks 2 -5). The sequence of this 765bp DNA 
insert was identical for all three strains, it had a G+C content of 64% and showed no 
significant homology with known genomic sequences. 
 
Association of deletions with insertions reveals InDel events 
One of the 15 identified genome rearrangement events (deletion 3A retrieved in two 
Australian isolates) was found to be a mere deletion with the genomic sequences flanking the 
5’ and 3’ borders of the 3451 bp deletion being directly joined (Fig. 4). Analysis of the other 
14 deletions revealed that the loss of DNA in a given strain with respect to the genome of 
Agy-99 was associated with the insertion of substituting sequences of varying sizes and 
unrelated to the deleted regions. The occurrence of insertions in combination with deletions 
reflects InDel events that have resulted in the substitution of original DNA. As an example, 
the larger (3784 bp) deletion 3B found in the isolates from Suriname and French Guyana was 
associated with the insertion of an unrelated DNA fragment (Fig. 4). 
In this case, the substituting DNA comprises the transposable element IS2404 plus an 
additional stretch of 163 bp. Interestingly, several of the analysed deletion borders seem to be 
in direct proximity to either IS2404 or IS2606. These ISE can be situated either in the 
genomic sequences flanking the deletion, or in the deleted parts, or in the substituting 
sequence stretches as in the case of deletion 3B. 
 
Analysis of genes encoded by the deleted DNA sequences 
The identified 15 distinct deletions identified 241 protein-coding sequences (CDS), 
representing 4.4% of the 5482 CDS annotated thus far for strain Agy-99 (T. Stinear, 
unpublished results). The number of deleted CDS ranged from 2 (RD4) to 54 (RD8), with an 
average of 18.6 CDS per deletion (Tab. 2). Twenty-two percent of all affected CDS were 
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predicted pseudogenes, mostly due to the presence of point mutations introducing frame-shift 
mutations or premature stop codons. The CDS were classified into 11 functional categories 
plus pseudogenes20. Predicted proteins involved in detoxification, unique hypothetical 
proteins, insertion sequences and pseudogenes were significantly overrepresented among 
these 241 deleted CDS. Genes involved in information pathways, metabolism and cell wall 
processes were underrepresented (Fig. 5). Eighty-nine of the deleted functional CDS had 
orthologues with >50% amino acid sequence identity to proteins from M. tuberculosis H37Rv 
genome. Only one of these orthologues (the transcriptional repressor Mce3R) is considered to 
be an essential gene required for growth of M. tuberculosis (Sassetti 2003).  
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Discussion 
In this report we describe the use of a plasmid-based DNA microarray for identifying DNA 
deletion polymorphisms in a collection of 30 M. ulcerans strains of geographically diverse 
origin. A set of plasmids randomly selected from an E. coli shotgun library of genomic DNA 
of M. ulcerans strain Agy-99 genomic plasmid library was spotted onto glass slides. This is a 
newly developed technology and it is highly suitable for situations where the complete 
genome sequence of a microorganism is not available. The prototype array used comprised 
232 useable plasmids, selected for giving a reproducible signal, which contained M. ulcerans 
genomic DNA fragments of approximately 2.5 kb, thus reaching a genome coverage of 15%. 
In spite of this incomplete coverage, 12 distinct genomic and 3 distinct virulence plasmid-
based RDs were identified. Fifteen distinct deletions with sizes between 1.8 kb to 53.1 kb 
were found and characterized in detail by sequence analysis within the 12 genomic RDs. The 
deletions identified were in most cases found in more than one M. ulcerans isolate, 
demonstrating that they are not events occurring during in vitro cultivation. Recombination 
events between adjacent copies of IS6110 in M. tuberculosis and IS100 in Y pestis have been 
shown to promote the deletion of intervening DNA segments21-25. Close association of RDs 
with the high copy number insertion sequence elements of M. ulcerans indicates that these are 
involved in InDel events in this mycobacterium.  
 
Although genome coverage with the prototype plasmid-based microarray used here was low, 
several geographical types of M. ulcerans could be differentiated. These were the African 
(including isolates from Ghana, Benin, Côte d’Ivoire, DRC, Angola and Togo), Papua New 
Guinean, Australian, the Asian (Japan and China), the South American (Suriname and French 
Guyana), the Mexican groups and an Australian subgroup differing from the other Australian 
isolates in RD3. Use of a microarray that covers the whole genome may lead to the 
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development of a genomic fingerprinting method urgently needed for micro-epidemiological 
studies aiming to characterise transmission pathways and environmental reservoirs. 
 
The 15 distinct genomic deletions we have identified affected 6.2% of the M. ulcerans Agy-
99 genome, or 4.4% of the genes. When a whole-genome microarray26 was used to compare 
genomic DNA of 100 M. tuberculosis isolates, 5.5% of the genes were found to be affected. 
Considering the limited genome coverage of the M. ulcerans prototype array used here, 
findings demonstrate a remarkably high degree of InDel diversity in M. ulcerans. In contrast, 
single nucleotide polymorphisms are rare27. The genome of M. ulcerans is about 500 kb 
smaller than that of the closely related M. marinum 
(http://www.sanger.ac.uk/Projects/M_marinum/). Our comparative analysis of the genomes of 
M. ulcerans isolates indicates that genome contraction is an ongoing process in this emerging 
pathogen. Studies in other groups of microorganisms indicate that genome reduction is 
usually associated with adaptation to a more stable environment. It remains to be investigated, 
to which ecological niche(s) in the environment or in host organisms M. ulcerans is adapting.  
 
Among the affected CDS, insertion sequences and pseudogenes were overrepresented, 
whereas genes associated with cell wall-processes, metabolic and information pathways were 
underrepresented. Genes involved in detoxification-adaptation, including the mammalian cell 
entry (mce) 3 operon were over-represented among the deletions. In M. tuberculosis the mce 
operons have been shown to code for genes important for entry and survival of the pathogen 
in mammalian cells 28, 29. The four mce operons of M. tuberculosis have homologues among 
other mycobacteria. In particular, the mce3 operon has been found in M. avium and M. 
smegmatis, while its deletion in M. bovis has been also documented30. The 12.7 kb region 
coding for the mce3 operon is located near the 3’ end of the RD2 element31 present in M. 
bovis, but absent in some strains of M. bovis BCG, which suggests the potential instability of 
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this region. Using a mouse model of intradermal infection, it has recently been shown, that M. 
ulcerans is initially captured by phagocytes 32. In vitro studies suggest that the M. ulcerans 
intracellular stage is transient, since phagocytic cells enter apoptosis-mediated cell death 
within one day. It would be interesting to investigate whether the Mce3 operon plays a role 
during the transient invasion of host cells by M. ulcerans.  
 
Among the deleted genes involved in cellular metabolism, 42% are dehydrogenases, central 
enzymes in anaerobic metabolism33. As speculated for M. tuberculosis34, the loss of such 
genes, important for survival in poorly oxygenated environments like in soil, could reflect the 
adaptation to a new life style. It remains to be determined whether M. ulcerans is primarily 
adapting to persist in a specialised environmental habitat, in arthropod hosts35 or in chronic 
wounds of mammalian hosts.  
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Table 1. Distribution of outlier plasmids among isolates 
       p: plasmid 
 
 
1. 8756 Japan 
2. 980912 China 
3. 842 Suriname 
4. 7922 French Guyana 
5. 5147 Australia 
6. 5142 Australia 
7. 9540 Australia 
8. 9550 Australia 
9. 940339 Australia 
10. 8849 Australia 
11. 5151 DRC 
 
 
 
 
 
 
12. 5150 DRC 
13. 940511 Côte d'Ivoire 
14. 940662 Côte d'Ivoire 
15. 94511Côte d'Ivoire 
16. 960658 Angola 
17. 960657 Angola 
18. 970680 Togo 
19. 970321 Ghana 
20. 970483 Ghana 
21. 970359 Ghana 
22. 940111 Benin 
 
23. 001441 Benin 
24. 940886 Benin 
25. 970104 Benin 
26. 940512 Benin 
27. 5143 Mexico 
28. 5114 Mexico 
29. 941331 PNG 
30. 9357 PNG 
 
CHAPTER 3. Genetic diversity in M. ulcerans                                  44 
 
 
 
0 
20 
40 
60 
80 
100 
Japan + China 
Japan_8756 China_980912 
20 
100 
0 
20 
40 
60 
80 
100 
Australia 
Australia_884 Australia_5142 Australia_5147 Australia_9549 Australia_9550 Australia_940339 
100 
0 
20 
40 
60 
80 
100 
Côte d'Ivoire + Ghana 
 
Côte_d ’ Ivoire _  
_94511 
Côte_d ’ Ivoire 
_940511 
Côte_d ’ Ivoire 
_940662 
Ghana_  
970321 
Ghana_  
970359 
Ghana_  
970483 
0 
20 
40 
60 
80 
100 
Benin 
Benin_001441 Benin_940512 Benin_940886 Benin_970104 Benin_970111 
0 
20 
40 
60 
80 
100 
Congo + Angola + Togo 
Congo_5150 Congo_5151 Angola_960657 Angola_960658 Togo_970680 
0 
20 
40 
60 
80 
100 
Mexico + French Guyana + Suriname 
Mexico_5143 Mexico_5114 French_Guyana_7922 Suriname_842 
80 
100 
0 
20 
40 
60 
80 
100 
PNG 
Png_9357 Png_941331 
p111 
p111 
P58 P58 
p144 
p305 
p92,299, 341, 111 
p144 
p92 
p305 
p170 
p111 
p92,88 
p153 
p360 
p124 
p291 
p170 
p88,111 
p360 
p92,291 
p124 
p153 
p315 
p61,8 
p58,144,100,34,341,60 
p315 
p144 
p8 
p61 
p58,60,341,100,34 
*p315 **p315 
*p315:217 **p315: 1040 
p188 
p341 
P111 
Benin 
Figure 1. Box plot analysis of the 30 M. ulcerans strains for identification of the plasmids 
yielding outlier signals  
The median of the data is represented by the line in the center of the rectangular box. The two 
ends of the rectangles represent the upper quartile UQ, corresponding to the 75th percentile 
(the value such that 75% of the data values are below it) and the lower quartile LQ, 
corresponding to the 25th percentile (the value such that 25% of the data values are below it). 
The inter quartile IQ is equal to UQ-LQ. The other two values shown are the maximum and 
minimum value of the data set: U1=UQ+1.5IQ; L1=LQ-1.5IQ. 
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Figure 2. Regions of differences including overlapping or adjacent plasmids  
 
 
RD Deletion Number Plasmid Strains 
 Size of  
deletion (kb) 
Number of 
CDS 
1 1 p8 SU/FG 11,1 14 
2 2 p34 SU/FG 6,5 – 7,0 4 
3A p58 AU1/AU2 3,5 5 
3 
3B p58 SU/FG 3,8 6 
4 4 p60, p61 SU/FG 1,8 – 2,4 2 
5 5 p88,  p153, p360 ME1/ME2 27,1 – 27,4 23 
6 6 p92 JP/CH/ ME1/ME2 19,7 24 
7 7 p100 SU/FG 14,9 – 15,5 13 
8 8 p124, p291 ME1/ME2 52,7 – 53,1 54 
9A p144 JP/CH 18,1 15 
 9 
9B p144 SU/FG 25,4 20 
 
10 10 p170 ME1/ME2 8,2 – 8,7 10 
11 11 p305 JP/CH 4,5 7 
12A p315 JP/CH 53,1 50  
12 
12B p315 SU/FG 35,2 – 35,7 32  
 
Table 2. Summary of the features of the 12 different RDs  
RD8 
RD5 
RD4 
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Figure 3. Additional polymorphism in RD5. 
Probing of genomic regions by PCR within the deletion obtained in the Mexican strains (lane 
28 and 29) as compared to the reference strain Agy-99 (lane 1) reveals an insertion of approx. 
750 bp for the M. ulcerans isolates from Asia and South America (lanes 2, Japan; 3, China; 4, 
Suriname; 5, French Guyana). This insertion is located within the 2,8 kb hybridizing region of 
Plasmid p88 between primers 5’-AATACCACCTCCTGGTGCAG (position 1238 bp) and 5’-
GACGACGATGAACTCCCAAT (position 1613bp). M, 1 kb marker; 6-11, Australia; 12-13, 
Congo; 14-16, Côte d’Ivoire; 17-18, Angola; 19, Togo; 20-22, Ghana; 23-27, Benin; 30-31, 
Papua New Guinea. 
 
1. Agy-99 
2. 8756 Japan 
3. 980912 China 
4. 842 Suriname 
5. 7922 French Guyana 
6. 5147 Australia 
7. 5142 Australia 
8. 9540 Australia 
9. 9550 Australia 
10. 940339 Australia 
11. 8849 Australia 
12. 5151 DRC 
13. 5150 DRC 
14. 940511 Côte d'Ivoire 
15. 940662 Côte d'Ivoire 
16. 94511Côte d'Ivoire 
17. 960658 Angola 
18. 960657 Angola 
19. 970680 Togo 
20. 970321 Ghana 
21. 970483 Ghana 
22. 970359 Ghana 
23. 940111 Benin 
 
 
24. 001441 Benin 
25. 940886 Benin 
26. 970104 Benin 
27. 940512 Benin 
28. 5143 Mexico 
29. 5114 Mexico 
30. 941331 PNG 
31. 9357 PNG 
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Figure 4.  Deletion 3A and 3B, showing two examples of a mere deletion event (3A), 
and of a deletion (3B) associated with an insertion event (InDel) 
GCGATCGCTTGATGTGAGAGCTGGTCGCTGGGCGCCCAGTCCCTGGAA 
Deletion 3A 
Deletion 3B 
TCGCTGGGCGCCCAGTCCCTGGAA 
CCGAGGTGCAGCGATCCTCGAGTG 
CGCTGTGCTTGATTGCTCCCGCCC 
 
CCGAGGTGCAGCGATCCTCGAGTG 
 
IS2404 
GCGATCGCTTGATGTGAGAGCTGG 
CGCTGTGCTTGATTGCTCCCGCCC 
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Figure 5. Comparison of the distribution of CDS functional categories between the RDs and 
the  M. ulcerans genome 
* depicts significant differences (p<0.05) 
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presented with active lesions while 234 (54%) were inactive cases.  Twenty-five of 202 active 
cases (12.4%) were recurrent cases. While the overall prevalence of active and inactive BU in 
the surveyed area was 4.4‰, the highest prevalence for active cases found in a particular 
settlement was 8%. Disease prevalence for active and/or inactive cases was higher in villages 
closer to the river Nyong (Figure 2). It was principally the rural, impoverished part of the 
population with limited geographical and economic access to health facilities that was affected. 
Sixty-six (28.2%) of the 234 cases with healed ulcers had severe chronic functional disabilities 
as a result of contraction deformities. In one case amputation of a finger was observed.  
Figure 3 shows the age and sex distribution of the 202 cases with clinically diagnosed active BU. 
A total of 115 (56.9%) of these were male and 87 (43.1%) were female patients, resulting in a 
sex ratio of 1.3 in favor of the male sex. The age of patients with active BU ranged from 2 to 90 
years with a median age of 14.5 years. Fifty per cent of the cases were under 15 years of age but 
no case was observed in children aged less than 2 years. The rate of illness did not differ 
significantly between the sexes or between different age groups.  
A total of 243 active BU lesions were found in the 202 active cases as some patients presented 
with multiple active lesions. Figure 4 shows the distribution of lesions according to where they 
were located on the body. Most lesions (93%) were located on the extremities, with the lower 
limbs being involved twice as frequently as the upper limbs. The distribution of lesions by site of 
localization on the body did not show any significant differences with respect to age or sex. The 
right or left distribution of lesions was similar both in the upper and the lower limbs (p = 0.20 
and p = 0.12, respectively).  
The mean duration of the lesions was 10.5 months (range: 1 week - 8 years; median 5.5 months). 
The clinical spectrum of lesions observed was as follows: 187 (92.8 %) of the cases presented 
with ulcers while 15 (7.4%) cases had non-ulcerative lesions (4 cases with nodules, 7 cases with 
plaques and 4 cases with edema). The average diameter of ulcerative lesions was 10.3 cm (range 
                              CHAPTER 4. Buruli ulcer in Cameroon-Rediscovered                            61 
1 – 107 cm). Bone involvement was clinically suspected in 30 (14.9%) of the 202 cases. 
Involvement of the eyes and genitalia was seen in two cases each. The extent of the lesion or its 
proximity to a joint (elbow, wrist, knee, ankle) made severe complications after spontaneous 
healing probable in 58 (28.7%) of the cases.  
 
A BCG vaccination scar was observed in 105 (52.0 %) of the 202 active cases. Multiple lesions 
defined as lesions present simultaneously on different parts of the body were observed more 
often in children (≤ 15 years old) without a BCG scar as compared to those with the scar (7/20 
vs. 1/30, P <0.01) suggesting a protective effect of this vaccination against more severe forms of 
BU in this age group. No such association was found for bone involvement in BU even after 
stratifying patients by age groups.  
 
One hundred and seventeen cases (57.9 %) said that a family member or relative had suffered in 
the past or was currently suffering from BU. In one family three children and in three other 
families two children were suffering at the same time from active BU. Relatives of patients with 
active BU, or members of their households who had had BU in the past, were asked when the 
illness had occurred. 75% reported that it was within the last three years. In 5% it was reported 
as having occurred more than 10 years ago. The different types of sources of (drinking) 
water (water tap, river, well, spring) were not significantly associated with the presence of BU. 
Probably patients go to the swamps for other domestic activities. 
 
An analysis of the health seeking behavior of the cases revealed that more than two thirds 
(67.3%) of them were exclusively under treatment given by traditional healers and less than 10% 
of them were being treated exclusively by trained health personnel. 
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Samples for laboratory confirmation of the presence of M. ulcerans in the lesions were taken 
from 164 (81.1%) of the 202 clinically diagnosed active cases. Samples could not be taken from 
the other 38 cases either because they presented with non-ulcerative lesions such as nodules, 
plaques or edema (n = 15) or because they presented with ulcers in an advanced stage of healing 
(n = 23). Direct microscopic examination of the 164 samples stained by the ZN technique 
revealed AFB in 38 (23.2%) cases. A total of 162 samples were analyzed by the IS2404 PCR 
technique (two PCR samples were lost). 135 (83.3 %) of these samples were positive for M. 
ulcerans DNA. In 34 cases, the both ZN staining and PCR were positive.  
 
Discussion 
During the last decade, the existence of BU disease in Cameroon has occasionally been 
suspected, but none of the cases notified on the basis of clinical symptoms was confirmed by 
laboratory diagnosis. In our study we identified on clinical grounds 436 persons with active 
(n=202) or inactive BU (n=234) in an endemic area situated in the Nyong basin in the Centre 
Province of Cameroon, where M. ulcerans disease was described for the first time more than 30 
years ago. M. ulcerans DNA was identified by the diagnostic IS2404 PCR assay in 135 (83.3%) 
of the 162 analyzed active cases with ulcerative lesions. However, confirmation by two 
independent laboratory methods as required according to WHO guidelines8 to positively 
diagnose BU was achieved in only 34 (17%) of these patients. For logistical reasons we had to 
renounce on systematic biopsy taking. If that had been possible more extensive analyses of 
specimens by culture of M. ulcerans, staining of AFB, PCR analysis and histopathological 
examination of excisional biopsies would probably have yielded far more ‘double positive’ 
laboratory results.  
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The differential diagnosis of the clinically identified 15 pre-ulcerative lesions (i.e., 4 cases with 
nodules, 7 with plaques and 4 with edema) was the most problematic, since it had to be done 
without any laboratory re-confirmation.  All cases with inactive (healed) BU had – for evident 
reasons – to be diagnosed exclusively clinically, too. Diagnostic misclassification may thus have 
overestimated the overall prevalence of BU. On the other hand, it is generally admitted that the 
clinical diagnosis of ulcerating BU by an experienced clinician is relatively straightforward in a 
known endemic area.17 Other common chronic ulcerative lesions encountered in Cameroon 
(tropical and venous ulcers, ulcers due to burns) can be differentiated from BU by their clinical 
aspects and case history. We therefore included all the 202 clinically diagnosed cases with active 
lesions in the analyses of the clinical presentation and of possible risk and protective factors. 
When supposing that clinical diagnosis together with partial confirmation by laboratory 
procedures was mostly correct, we may ask, alternatively, whether it was likely that we missed a 
substantial number of cases. The delimitation of the survey area was empirical, depending 
substantially on the ability of the local population to identify the disease. However, the 
population and peripheral local health personal appeared to identify BU even in its early, pre-
ulcerative forms surprisingly well. On the other hand, we may have missed cases because 
presentation was voluntary and this could have resulted in a selection bias. Therefore the 
survey’s results may rather have underestimated than overestimated prevalence. On various 
occasions we even noticed traditional healers forbidding their patients to present themselves to 
the survey team. People with inactive BU were not included in the analysis of the clinical 
presentation and possible risk and protective factors, for two reasons. Firstly, we assumed that 
the presentation of cases on a voluntary basis would induce a selection bias towards active cases. 
Secondly, case-histories from people with lesions were likely to be less accurate when the 
disease was acute some years ago.  
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The endemic area had characteristics similar to those found in foci elsewhere 4,5,6,7 and the 
clinical characteristics of active cases notified resemble what has been found in similar 
situations.14 The endemic area is located in the swampy banks along the large meanders of a 
slow flowing river Nyong and some of its affluents, and it is isolated. The frequency of identified 
cases diminished with distance to the river. Similar to findings in Côte d’Ivoire 18, more than half 
of the cases were children =/< 15 years old with the highest rate of infection in the group of 10-
14 years. No preponderance of women in the group of adult (=/> 15 years) patients was found, as 
was reported in earlier descriptions of this focus and in other studies.6-13The ulcerative forms 
predominated in prevalent active BU cases; our finding of 92.8% compares with 89.5% or 96.4% 
found in prevalence studies in Côte d’Ivoire and in Benin, respectively.5,6 However, in a more 
recent study, performed on 1700 patients from Bénin (from 1997 to 2001), there was no 
statistical difference between the percentage of ulcerated and non-ulcerated forms. The 
increasing number of non-ulcerated forms detected from 1997 to 2001 is a result of increasing 
activity of public health programs that raised awareness of BU clinical forms (Debacker et al, 
manuscript in preparation). 
 
Our study showed a relatively high frequency (14.9%) of bone involvement, although similar 
frequencies have been reported in other studies.19 This high frequency may have been due to a 
selection bias due to our case-finding method and use of clinical diagnosis. Lesions on the limbs 
were predominant. In the first - restricted - case series of the Nyong focus upper limbs were 
predominantly affected, but our findings confirm the general finding of lower limbs being most 
affected.13 Even after stratification for sex and age, no unequal right-left distribution of lesions 
on limbs as reported in some other studies 4,17,18 was found. Similarly in a recent study in Bénin, 
there were no significant differences between the number of lesions on the right or left limbs 
(Debacker et al., manuscript in preparation).  
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In 1969, the Uganda Buruli Group demonstrated in a controlled trial that BCG vaccination 
confers partial protection against BU during at least six months.20 This finding was confirmed by 
Smith and colleagues in 1974.21 In Benin, BCG vaccination appeared to partially protect children 
of less than 15 years of age with confirmed BU against the osseous forms of BU.22 In our study 
population children not vaccinated with BCG appeared to have a significantly higher risk of 
multiple lesions, confirming the partial protective effect of BCG vaccination against severe 
forms of BU in children.  
 
BU tends to affect several members of the same family which was already observed in early 
studies of the disease in Uganda.2 Reported figures about the proportion of households with 
several BU cases are scarce, varying between 0% and 5%.13, 23 Our figure of almost 58% of a 
history of cases in the family or among people living in the same compound appears high. But it 
is not really comparable with figures communicated by other studies as our questionnaire did not 
allow differentiating between other family members suffering currently from BU and family 
members known to have suffered in the past from BU. The data suggest that within the endemic 
area scattered disease foci of different importance subsist during time.  
 
Even with only partial laboratory re-confirmation, we conclude on the basis of clinical and 
epidemiological evidence that the area surveyed constitutes a focus of emergent endemic BU of 
considerable magnitude. The accumulation of family cases during the past three years suggests 
BU to be recently re-emerging on a larger scale in the survey area. However, this focus has 
probably existed without interruption and - when considering the distribution of active and 
inactive cases - without major transposition of the different individual foci, for more than thirty 
years in a well-circumscribed area without triggering off any intervention by health authorities. 
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Further support was given to the idea that the disease had never really disappeared from the area 
by the fact that it was evidently well known and described by the local population.  
 
Patients’ preference of traditional medicine reflects a situation where the health system has had 
nothing to offer to assist these patients and where, consequently, the population has lost 
confidence in the ability of the health system to assist. Currently, surgery is the only proven 
effective treatment of M. ulcerans disease.16 Limiting factors include inadequate surgical 
facilities, need for prolonged stay in hospital and high treatment costs. Estimating the mean 
duration of the disease without medical intervention to be one year, the annual incidence could 
be estimated to be a 100-150 new cases of BU in an area largely identical with the survey area. 
With more than 25% of these patients being at high risk to develop severe long-term disabilities, 
a comprehensive public health intervention by health authorities and the health districts 
concerned is urgently needed. Control strategies promoted by the Global Buruli Ulcer Initiative 
include strengthening of the health care capacity in BU endemic areas by upgrading surgical 
facilities, health education and staff training in the communities to promote early detection and 
rapid referral, development of motivational strategies and rehabilitation of those already 
deformed by the disease.16 
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FIGURE 1. Presentation of fully developed Buruli ulcer lesions and of a contracture deformity 
resulting from scarring.  
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FIGURE 2. Prevalence of active and inactive Buruli ulcer cases in 83 villages and settlements in 
the study area in Cameroon along the Nyong River and some of its main tributaries. The survey 
area encircled.  
 
FIGURE 3. Age (in years) and sex distribution in 202 clinically diagnosed patients with active 
Buruli ulcer.  
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FIGURE 4. Distribution of active lesions in 202 clinically diagnosed patients with Buruli ulcer. 
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Abstract 
Buruli ulcer, an infection caused by Mycobacterium ulcerans is after tuberculosis and 
leprosy the third most common mycobacterial disease. The mode of transmission of M. 
ulcerans is not exactly known, but since Buruli ulcer often occurs in focalized swampy 
areas, it is assumed that there is a reservoir of the pathogen in stagnant water. Buruli ulcer 
usually starts as a painless nodule and can lead to massive destruction of skin, subcutaneous 
tissue and eventually muscle and bone. Currently the only recommended treatment is wide 
surgical excision. In this report we describe the development of a real-time PCR method for 
the quantification of M. ulcerans DNA (IS2404 TaqMan). The highly specific assay is 
based on the detection of the M. ulcerans specific insertion sequence IS2404. The IS2404 
TaqMan assay turned out to be about ten times more sensitive than the available 
conventional PCR-based diagnostic test. It is demonstrated that the Taqman IS2404 assay is 
suitable for the quantitative assessment of the dissemination of the mycobacteria in Buruli 
ulcer lesions. Prototype results obtained with excised tissue from a patient with a late pre-
ulcerative Buruli ulcer lesion reconfirmed earlier histopathological findings indicating that 
tissue damage occurs far beyond the regions in which large numbers of mycobacteria are 
detectable. The IS2404 TaqMan assay should be a useful tool for both diagnosis and 
research into the pathology and mode of transmission of this still inadequately investigated 
mycobacterial disease. 
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Introduction 
Mycobacterium ulcerans is a slow growing environmental mycobacterium, which causes a 
disfiguring condition known as Buruli ulcer. After tuberculosis and leprosy Buruli ulcer is 
the third most common mycobacterial infection in humans. It often occurs in people who 
live close to rivers and stagnant bodies of water. M. ulcerans infections have been found in 
more than thirty tropical and sub-tropical countries of Africa, Asia, Latin America and the 
Western Pacific, but are most common and severe in West Africa (1). 
The mode of transmission of M. ulcerans is not clear, but it is assumed that the 
environmental pathogens enter the body through small lesions in the skin (1,5). Aquatic 
insects may be involved in some cases (1,17). After entry, the bacteria proliferate in the 
subcutaneous tissue. In African patients, early lesions are characterized by coagulative 
necrosis of lower dermis and subcutaneous fatty tissue associated with some calcification. 
Production of mycolactone (12), a toxin with affinity for fatty cells (11) may be important 
for the pathogenesis of the disease by causing necrosis and thus providing a favorable 
milieu for the mycobacteria. It is likely, however, that additional bacterial factors are 
involved in the pathogenesis (9). Even in the most minimal lesions, necrosis of fatty tissue 
seems to be a primary event (18). In contrast to other pathogenic mycobacteria, M. ulcerans 
is not a facultative intracellular pathogen, but is found primarily as extracellular 
microcolonies (13,18) 
Depending on its progression, Buruli ulcer has different clinical manifestations. The disease 
often starts as a painless swelling in the skin and as it progresses, all elements of the skin 
become affected. The early pre-ulcerative forms (nodules, papules, plaques and edemas) are 
followed by the ulcerative stage. Necrosis of the subcutaneous fatty tissue with vascular 
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occlusion results in sloughing and secondary ulceration of the overlying skin. Acid-fast 
bacilli (AFB) stained by the Ziehl-Neelsen (ZN) technique in tissue sections seem to be 
largely confined to the necrotic slough and surrounding necrotic fatty tissue. In the late 
stages massive areas of skin, subcutaneous tissue and sometimes muscle and bone are 
destroyed, leading to gross deformities. If a healing response takes place, fibrosis, scarring, 
calcification and contractures with permanent disabilities may result (29). To date the 
treatment of choice is surgery, since current antimicrobial therapies appear to be 
ineffective, but recurrence of the disease after surgical treatment is a common problem that 
may be due to incomplete removal of the mycobacteria and inadequate excision. 
Early treatment of M. ulcerans disease provides a better outcome than treatment of the 
ulcerative forms, but is often impaired by the difficulties of diagnosis. The commonly used 
diagnostic tests are: i) detection of mycobacteria by ZN staining, a technique that lacks 
sensitivity and specificity, ii) culture of M. ulcerans, which may take several months, iii) 
detection of characteristic histopathological changes in excised tissue and iv) detection of 
M. ulcerans DNA by PCR, representing a rapid, sensitive and specific diagnostic method  
(20). IS2404, an insertion element present in multiple copies in the M. ulcerans genome is 
commonly used as target sequence for this purpose (25). IS2404 is specific for M. ulcerans 
and encodes a 328 amino acids long transposase (26). 
 
In this report we describe the development of a PCR method for the quantification of M. 
ulcerans DNA by monitoring the real-time amplification of IS2404, using the TaqMan 
system (IS2404 TaqMan). Beyond the possibility of measuring the starting amount of target 
DNA in clinical specimens and other samples, real-time PCR has several advantages over 
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the conventional end-point PCR. These include reduction of risk of contamination, by 
eliminating the post-PCR processing and a diminished sensitivity to PCR inhibitors. By 
applying IS2404 TaqMan PCR to samples coming from Buruli ulcer patients, it will be 
possible to correlate dissemination of M. ulcerans with progression of the disease. The 
method may also help to determine the optimal extent of surgical excision in order to 
reduce recurrence. 
 
Materials and Methods 
Mycobacterial isolates 
Mycobacterial isolates that have been employed in this study are listed in Table 1. Clinical 
isolates were identified to the species level by the partial sequencing of the 16S ribosomal 
DNA (rDNA) gene and by conventional methods (19).  
 
Clinical specimens 
Samples of about 100mg were taken from tissue excised from a Buruli ulcer patient (male, 
12 years old) in Amasaman, Ghana with a pre-ulcerative plaque lesion at the ventral side of 
his left distal forearm. Care was taken to avoid cross-contamination among the different 
sample areas.  
Cotton swabs were used to collect diagnostic samples from the base of undermined margins 
of lesions of Buruli ulcer patients with ulcerative lesions. The samples were maintained in 
the cold chain until analyzed. 
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DNA preparation 
Extraction of DNA from cultivated mycobacteria was done as previously described by 
Telenti et al. (28). The tips of the cotton swabs were cut and heated for 30 minutes at 95°C 
in screw cap tubes containing 600µl of extraction buffer (0.2% SDS, 0.05M NaOH). After 
a brief centrifugation, 40µl of a 20mg/ml proteinase K solution was added to the 
supernatants. After 30 minutes of incubation at 60°C the samples were vortexed for 2 
minutes with 200µl of 100µm glass beads and the DNA in the supernatants was 
precipitated and washed with ethanol. After another washing with acetone and air drying, 
the precipitated DNA was resuspended in 60µl of water and 0.5µl of the template solutions 
were used for PCR analysis. 
Tissue samples of about 100mg were heated for 1 hour at 95°C in 500µl of extraction 
buffer (50mM Tris-HCl, 25mM EDTA, 5% monosodium glutamate). One hundred 
microliters of a 100mg/ml lysozyme solution were added. After 2 hours of incubation at 
37°C, 70µl Proteinase K-10X buffer (100mM Tris-HCl, 50mM EDTA, 5% SDS, pH 7.8) 
and 10µl of a 20mg/ml proteinase K solution were added. After incubation at 45°C 
overnight, the samples were subjected to bead beater (Mikro-Dismembrator, Braun Biotech 
International) treatment with 300µl of 0.1mm zirconia beads (BioSpec Products) at 3000 
rpm for 7 minutes. Beads and undigested tissue fragments were removed by brief 
centrifugation and the supernatants were transferred to fresh tubes. An equal amount of 
phenol-chloroform (Fluka) was added and the DNA contained in the upper phase was 
precipitated with ethanol and resuspended in 150µl of water. The DNA yield was measured 
using a spectrophotometer (GeneQuant) and 50ng of DNA per each sample were subjected 
to amplification with conventional and real time PCR. 
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Conventional PCR 
DNA was amplified in a 50µl reaction mixture containing 1µM of each primer (MU1, 
MU2; Table 2), 2.5U of HotStart DNA Polymerase (Qiagen), 200µM of each 
deoxyribonucleotide triphosphate, 1.5mM MgCl2 and 1xPCR Buffer (Qiagen). PCRs were 
performed in a Gen Amp PCR System 2400 (Perkin Elmer) thermal cycler with the 
following protocol: denaturation at 94°C for 10 minutes, amplification for 35 cycles of 
94°C for 1 min, 60°C for 1 min and 72°C for 1 min, and a final extension at 72°C for 7 
min. Ten microliters of amplified DNA were subjected to electrophoresis in a 1% agarose 
gel and detected by ethidium bromide staining and UV transillumination. A 1Kb ladder was 
used as a size marker. 
 
Real-time PCR 
Primer and probe sequences (Table 2) were selected from a region of the IS2404 sequence 
with minimal homology with human DNA. The probe was labeled with the fluorescent 
dyes 5-carboxyfluorescein (FAM) on the 5’ end and N,N,N’,N’-tetramethyl-6-
carboxyrhodamine (TAMRA) on the 3’ end. When the dyes are close to each other, the 5’ 
reporter fluorophore (FAM) transfers laser induced excitation energy to the 3’ quencher 
(TAMRA). When the oligoprobe hybridizes to its template, the fluorophores are released 
by the 5’-3’ exonuclease activity of the TaqPolymerase, leading to the separation of the 
dyes in solution. Once they are separated the reporter emission is no longer quenched and it 
is possible to measure the increasing fluorescence which is proportional to the amount of 
target DNA produced (15). DNA extracted from M. ulcerans strain Agy98 was used as 
standard in all experiments. 
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Real-time PCR reaction mixtures contained template DNA, 0.3µM of each primer, 0.1µM 
of the probe and TaqMan Universal PCR Mastermix (Applied Biosystem) in a total volume 
of 25µl. Amplification and detection was performed with the ABI Prism 7700 Sequence 
Detection System, using the following profile: 1 cycle of 50°C for 2 min, 1 cycle of 95°C 
for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 1 min. Analyses were done in 
triplicates. For quantification, an external standard curve with M. ulcerans Agy98 DNA 
serially diluted over 6 logs was used. Negative controls were included in each amplification 
experiment. To analyze the potential inhibitory effect of human DNA on the real-time PCR 
reaction, increasing amounts of human genomic DNA from 10 to 1000ng were added to a 
fixed amount of 20fg of M. ulcerans DNA per PCR reaction mix.  
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Results 
Development of an IS2404 based real-time PCR assay 
Using IS2404, an insertion sequence unique for M. ulcerans as target, an ABI Prism 
Sequence Detection System (TaqMan) quantitative real-time PCR method was developed. 
Primers F1 and R1 comprised residues 406 - 424 and 465 – 449 in the genebank IS2404 
sequence AF003002, respectively (Table 2). They were used in combination with the probe 
P1 comprising residues 447 – 426. The standard curve obtained with a serially diluted M. 
ulcerans genomic DNA preparation was linear over six orders of magnitude with a 
coefficient of correlation of 0.999 and a slope of 3.51 corresponding to a PCR efficiency of 
>90% (Figure 1). Assuming that 1 genome copy corresponds to 5fg of DNA (27), the 
detection limit was 0.2 genome copies per reaction mixture. Since it is expected that the 
genome of M. ulcerans isolates contain approximately 50 – 100 copies of IS2404, the 
detection limit thus corresponded to 10 - 20 copies of IS2404. With amounts of M. ulcerans 
DNA equivalent to 0.2 to 200000 genome copies, Ct values ranging from 35 to 16 were 
obtained with a coefficient of variation less than 2 (Table 3).  
 
The potential inhibitory effect of human genomic DNA was evaluated by spiking fixed 
amounts of M. ulcerans DNA with increasing concentration of human genomic DNA 
(Table 4). Human DNA on its own yielded no signal and amounts of up to 500ng of human 
DNA per reaction mixture had no inhibitory effect on the amplification of a starting amount 
of 20fg of M. ulcerans DNA. Only addition of 1µg of human genomic DNA resulted in 
some inhibition (Table. 4). This was compatible with M. ulcerans DNA quantification in 
clinical specimens, since amounts of human DNA in extracts from affected tissue were 
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much smaller (50ng). Genomic DNA of none of the other 22 mycobacterial species tested 
(Table 1) produced an amplification product, demonstrating the high specificity of the 
IS2404 TaqMan assay. 
 
Use of the IS2404 TaqMan assay for the analysis of clinical specimens 
Swab samples taken from the undermined edges of lesions from patients with ulcerative 
forms of Buruli ulcer were subjected to conventional and quantitative PCR. The 
conventional PCR allowed the detection of the expected 568bp band, with some variation 
in the intensity of the signal among the different samples (Fig 2). Southern blot 
hybridization confirmed that IS2404 derived PCR products were obtained (data not shown). 
The real-time PCR revealed more than 400 fold differences in the amounts of M. ulcerans 
DNA, ranging from 13 to 5267 genome copies/µl of extract (Table 5). 
 
To demonstrate the suitability of the IS2404 TaqMan assay for the quantitative assessment 
of the dissemination of the mycobacteria in Buruli ulcer lesions, a surgical specimen widely 
excised from a patient with a non-ulcerative plaque on the ventral side of the left forearm 
was analyzed. In addition to the firm and slightly elevated lesion (B, B* and C in Fig. 3), 
the surgeon had excised a clear margin of normal tissue (A and A* in Fig. 3). In the centre 
of the plaque a more elevated region (C in Figure 3) was detectable, which was presumably 
the location of a papule or nodule in the earlier stage of the disease. Nine samples of about 
100mg extending from the skin into the subcutaneous fatty tissue were taken at different 
distances from this centre of the lesion in a plane parallel to the skin surface (level 1 in 
Fig.3). In the center of the lesion, deep subcutaneous tissue and fascia were also severely 
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affected. The surgeon therefore removed two additional layers into the deeper tissues at this 
location, with the lowest one (level 3 in Fig. 3) extending deep down to the flexor tendon. 
Six samples were taken from these tissue specimens (levels 2 and 3 in Fig. 3), which 
exhibited pathologic changes both in color and texture.  
 
Result of a conventional PCR analysis with the tissue samples demonstrated the presence of 
M. ulcerans DNA in all the specimens taken and already gave some indication that the 
amounts of mycobacterial DNA template present in the samples varied (Fig. 4). But only 
the result of the IS2404 TaqMan assay fully demonstrated the dramatic differences in the 
burden of M. ulcerans at different locations of the lesion (Fig. 3). The specimen taken from 
the middle layer in the very centre of the lesion (C2 in Fig. 3) contained about 20 times 
more mycobacterial DNA than the 14 other samples altogether. Three neighboring samples 
from layers 1 and 2 still contained 1-2% of the amount of M. ulcerans DNA found in the 
focus sample. Levels of M. ulcerans DNA in the additional samples from the plaque lesion 
(from B, B* and level 3 in Fig. 3) and in the excised margins of apparently healthy tissue 
(A and A* in Fig. 3) were comparable. None of these samples contained more than 0.3% of 
the amount of M. ulcerans DNA found in the sample with the highest burden. Values from 
split tissue samples showed little variation (data not shown), indicating that the yield of M. 
ulcerans DNA obtained with the optimized DNA extraction method used was quite 
reproducible. Nevertheless the absolute values presented may represent underestimates, 
since release of mycobacterial DNA may still have been incomplete.   
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Discussion 
In this paper the development of an IS2404 based real-time PCR assay for the 
quantification of M. ulcerans DNA is described. IS2404 is also the target of a conventional 
PCR assay (24) recommended in a slightly modified form  (20) by WHO as test for the 
confirmation of the clinical diagnosis of M. ulcerans infection. While conventional PCR 
assays basically provide end-point measurements suitable for qualitative “yes/no” results, 
the real-time IS2404 TaqMan assay quantifies the starting concentration of mycobacterial 
DNA by monitoring the amount of reaction product during the exponential phase of the 
amplification cycles. The remarkably broad dynamic range of the IS2404TaqMan assay 
allowed us to analyze samples with widely varying content of M. ulcerans DNA without 
prior estimation of template concentrations. The IS2404 TaqMan assay exhibited an about 
ten times higher sensitivity than the conventional IS2404 based PCR, which has been 
described to have a detection limit of two genome copies. No amplification products were 
detected when the DNA of 22 other mycobacteria species were tested with the IS2404 
TaqMan assay, which reconfirms specificity data described for the conventional IS2404 
PCR (24). 
 
As expected, IS2404 TaqMan analyses demonstrated that the amounts of  M. ulcerans 
DNA present in extracts from wound swabs as taken routinely for PCR confirmation of 
clinical diagnosis vary widely. Endpoint determinations by conventional PCR did not fully 
reflect these differences. Amounts of DNA in the swab extracts were at the lowest end 
close to the detection limit of the conventional PCR. Already small variations in the 
reaction conditions may in such cases cause inconsistencies in the results obtained in 
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parallel analyses performed by the same laboratory or by different laboratories. 
Introduction of the more sensitive IS2404 TaqMan assay will thus improve PCR 
confirmation of clinical diagnosis of Buruli ulcer and yield fewer false negative results.  
Due to their high sensitivity, PCR based assay systems are prone to yield false positive 
results caused by cross-contamination. Real time PCR reduces this risk considerably, by 
avoiding the post-PCR handling of the samples containing vast amounts of PCR products. 
Nevertheless it is advisable, even with the IS2404 TaqMan assay,  to strictly adhere to the 
‘three-room’ principle: room one for the preparation of the PCR reaction mix, room two for 
the processing of samples and the preparation of template DNA in a biosafety cabinet and 
room 3 for PCR amplification. 
 
Apart from the confirmation of clinical diagnosis, real-time PCR tests have a broad range 
of potential applications including the quantification of target DNA in clinical specimens 
and environmental samples. M. ulcerans is an environmental mycobacterium and it appears 
that infection with it is related to swampy environments. M. ulcerans has been isolated 
from aquatic bugs belonging to the genus Naucoris (17) and detected by conventional PCR 
both in water samples (23) and in water insects (21) (22) (25). The IS2404 TaqMan assay 
may help in future to identify the major environmental reservoir(s) of this pathogen. 
 
Currently surgery is the only proven effective treatment of M. ulcerans disease (3). Lesions 
in advanced stages, i.e. late pre-ulcerative and ulcerated forms may require excisions that 
include deep fascia and sometimes even muscle. In all forms excisions must include healthy 
tissue at the lateral and deep margins. The IS2404 TaqMan assay may help to answer the 
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question of how wide surgical excision has to be to avoid recurrences. Currently the 
decision on the size of excision is largely left to the experience and judgment of the 
surgeon. The surgeon has to compromise between the risk of recurrence and an oversized 
excision, associated with the need for more extensive skin grafting, increased risk of 
secondary infections and longer hospitalization. IS2404 TaqMan analyses will be more 
suitable for the analysis of the dissemination of mycobacteria in Buruli ulcer lesions than 
the more labor-intensive and less specific and sensitive enumeration of AFB in ZN stained 
tissue sections. Cultivation of M. ulcerans is not a suitable quantification method, since 
decontamination methods have a detrimental effect on the organism and primary cultivation 
requires between six and eight weeks or longer  (20). As a typical example, data obtained 
with excised tissue from a patient with a pre-ulcerative plaque lesion on the forearm are 
presented in this report. The heaviest mycobacterial burden was found in a sample of 
subcutaneous tissue located about 0.5cm below the surface in the centre of the lesion. It is 
likely that this sample is part of the original focus of the infection, which seemed to be still 
relatively small in this late pre-ulcerative stage, since three other samples taken from the 
centre of the plaque (C in Fig. 3) contained less than 2% of this amount of M. ulcerans 
DNA. Levels were still lower in all the other samples taken from more peripheral affected 
or from macroscopically healthy tissues. In agreement with these findings, 
immunohistopathological studies of Buruli ulcer lesions have indicated that tissue necrosis 
extends far beyond the regions in which microcolonies of AFB are detected (4). These 
results support the hypothesis that diffusible toxins are associated with the pathology of M. 
ulcerans infection (9,12). After introduction of the mycobacteria into the dermis or 
subcutaneous tissue there is presumably a latent phase during which the slow growing 
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bacteria proliferate and elaborate sufficient toxin to destroy the surrounding tissue. The 
subsequent necrosis, especially of fatty tissue, may then provide a favorable milieu for 
further proliferation (18). Analyses of the spreading of the mycobacteria may contribute to 
our understanding of the pathogenesis of Buruli ulcer and guide surgical treatment. Lesions 
appear to progress differently and it is possible that differences in the dynamics of 
mycobacterial spreading can be distinguished, that require different types of intervention. It 
is remarkable, that levels of M. ulcerans DNA in affected tissue outside the centre of the 
plaque lesion and in the excised margins of apparently healthy tissue were comparable. 
During the collection of tissue samples and the preparation of template DNA extreme care 
was taken to avoid cross-contamination. Nevertheless, it cannot be completely excluded, 
that at least part of the signals observed with these more peripheral samples are related to 
contamination from the infection focus during excision. However based on concentration 
gradients observed with excised samples from more advanced Buruli ulcer lesions 
(unpublished results) it appears likely that the signals observed  reflect spreading of 
relatively small numbers of mycobacteria. Removal of the complete burden of M. ulcerans 
may not be possible even with very wide excision. After surgery, the primed immune 
system may, however, be able to control small numbers of residual mycobacteria devoid of 
a protective cloud of necrotic tissues and bacterial toxin(s).  
 
To date no antibiotic treatment has proven to be consistently effective in the treatment of 
Buruli ulcer (3). In a mouse footpad model of Mycobacterium ulcerans infection, treatment 
with a combination of rifampin and amikacin has yielded promising results (6) and clinical 
trials with combinations of antibiotics are currently in progress (10). Monitoring of the 
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response to chemotherapy may represent another useful application of the IS2404 TaqMan 
assay. Real time PCR has been used to monitor the efficacy of antimalarial (14), 
antibacterial (2) and antiviral (16,30) treatment.  In the case of an IS6110 TaqMan assay for 
M. tuberculosis it has been found, that the amounts of DNA quantified in sputum 
corresponded well with the numbers of AFB counted by microscopy (7). Before initiation 
of antituberculosis therapy, measures of AFB, M. tuberculosis DNA, and cultivable bacilli 
were comparable, suggesting that quantification of DNA is a good method for measuring 
the initial bacillary load. However, the decline in cultivable bacilli in the specimen did not 
correlate with the rate of disappearance of both AFB and M. tuberculosis DNA. Therefore, 
these tests were not appropriate for monitoring treatment efficacy (7). In contrast, the rapid 
disappearance of M. tuberculosis mRNA suggested that it is a good indicator of microbial 
viability and a useful marker for monitoring the efficacy of chemotherapy (8). The same 
may hold true for M. ulcerans disease which may also require the development of a real 
time RT-PCR system. IS2404 encoding a 328 amino acids long transposase should be a 
suitable target also for such an assay.  
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FIG. 1. Standard curve generated by the analysis of known amounts of genomic M. 
ulcerans DNA with the IS2404 TaqMan assay. The regression line calculated for the data 
points is shown; the coefficient of correlation is more than 0.99. 
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TABLE 1. List of mycobacterial strains used in this study 
 
Mycobacterial species  Source  Medium  Temperature  
M. abscessus  ATCC 19977  mod. LJ*  35°C  
M. africanum  Swiss NCM *** mod. LJ  35°C  
M. avium subsp. avium  MAC101  mod. LJ 35°C 
M. bohemicum  Clinical isolate  mod. LJ 35°C 
M. bovis  ATCC 19210  mod. LJ 35°C 
M. bovis biovar. BCG  ATCC 35734  mod. LJ 35°C 
M. bovis subsp. caprae  Clinical isolate  mod. LJ 35°C 
M. chelonae  DSM 43804  mod. LJ 35°C 
M. fortuitum  ATCC 49403  mod. LJ 35°C 
M. gordonae  Pasteur 14021.001  mod. LJ 35°C 
M. haemophilum  ATCC 29548  MB 7H10** 28°C 
M. intracellulare  Clinical isolate  mod. LJ 35°C 
M. kansasii  NCTC 10268  mod. LJ 35°C 
M. lentiflavum  Clinical isolate  mod. LJ 35°C 
M. malmoense  NCTC 11298  mod. LJ 35°C 
M. marinum  ATCC 927  mod. LJ 28°C 
M. scrofulaceum  Pasteur 14022.0031  mod. LJ 35°C 
M. simiae  Clinical isolate  mod. LJ 35°C 
M. smegmatis  Pasteur 14133.0001  mod. LJ 35°C 
M. terrae  Clinical isolate  mod. LJ 35°C 
M. tuberculosis H37Rv  Pasteur 14001.0001  mod. LJ 35°C 
M. xenopi  Clinical isolate  mod. LJ 35°C 
 
a
 mod. LJ, modified Löwenstein-Jensen; MB 7H10, Middlebrook agar with 10% oleic acid-
albumin-dextrose-catalase enrichment supplement with 0.4% ferrum-ammonium-citrate. b 
Swiss NCM: Swiss National Centre for Mycobacteria, Zurich, Switzerland. 
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TABLE 2. Primer and probe sequences used for the IS2404 TaqMan assay and 
conventional PCR 
Sequence (5'-3')     Reference 
Primers 
F1 ATTGGTGCCGATCGAGTTG    This study 
R1 TCGCTTTGGCGCGTAAA     This study  
MU1 GGCAGGCTGCAGATGGCATA    Ross et al. 
MU2 GGCAGTTACTTCACTTGCACA    Ross et al. 
Probe 
P1 FAM-CACCACGCAGCATTCTTGCCGT-TAMRA This study 
 
TABLE 3. Measurement of replicate standard curves ranging from 0.2 to 200,000 genomes 
of M. ulcerans per reaction mixturea 
Genome copy    LOG copy Ct for the following reactions 
number      number 1          2          3          Mean     SD     CV 
0.2           -0.70 35.0    35.5    34.6       35.05     0.49     1.39 
2           -0.30 31.5    32.5    31.8       31.94     0.52     1.62 
20            1.30 29.1    29.1    28.7       28.95     0.20     0.70 
200             2.30 26.0    25.7    26.0       25.88     0.18     0.68 
2000            3.30 22.2    22.2    22.3       22.25     0.02     0.10 
20000            4.30 18.8    18.9    18.8       18.85     0.06     0.29 
200000            5.30 15.8    15.8    16.0       15.89     0.11     0.68 
a
 Abbreviations: Ct, threshold cycle number; SD, standard deviation; CV, coefficient of 
variation. 
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TABLE 4. Evaluation of the potential inhibitory effect of human genomic DNA in 
quantification of M. ulcerans by IS2404 TaqMan 
 
Human genomic DNA  Ct values 
per PCR reaction (ng) 
0    28.51   
10    28.69 
50    28.48 
100    28.37 
200    28.37 
500    28.85 
1000    30.20 
 
 
FIG. 2. Amplification products obtained by conventional diagnostic IS2404 PCR with 
DNA extracted from swabs used for taking samples from undermined edges of Buruli ulcer 
lesions (lanes 1 to 15). The lane marked "neg" was loaded with an aliquot from a negative 
control amplification containing no template DNA. 
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TABLE 5. Numbers of genome copies of M. ulcerans in swabs of patients with Buruli 
ulcer 
 
Sample           copy no/µl*      SD            CV 
1   20              1.1            10.3 
2   106             4.0            7.5 
3   240             10.0          8.3     
4   13               0.4            5.9 
5   20               0.9            9.4 
6   333             11.5          6.9 
7   720             28.2          7.9 
8   16               2.5            31.4  
9   46               26.5          11.5 
10   5267           115.5        4.4 
11   460             200.0        8.7 
12   105             1.5            2.9  
13   14               0.6            8.9 
14   970             7.1            1.5 
15   1090           21.2          3.9 
 
a
 60 µl of extract was obtained per swab. 
b
 SD, standard deviation. 
c
 CV, coefficient of variation. 
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TABLE 6. Measurement of genomic M. ulcerans DNA from tissue samplesa 
 
 
Reaction 1e  Reaction 2e  Reaction 3e  Mean   SDb   CVc 
 
286   308   328   307   21   6.75 
245   200   270   238   35   14.73 
32   31   30   31   0.7   2.28 
39   34   36   36   2   6.59 
402   391   433   409   22   5.42 
8,333   8,392   NDd   8,362   42   0.50 
7,782   8,340   8,388   8,170   337   4.12 
1,273   1,483   1,550   1,435   144   10.04 
351   327   325   334   15   4.24 
502,378  499,420  493,558  498,452  4,489   0.90 
4,585   4,674   4,794   4,684   105   2.25 
596   585   489   557   59   10.54 
160   161   ND   161   0.4   0.25 
153   165   161   160   6   4.08 
127   119   123   123   4   3.22 
 
a
 Corresponding to 1 µl of tissue extract (100mg/150µl), the values are ordered referring to 
tissue samples coming from left to right and from levels 1 to 3 according to the schema of 
the lesion shown in Fig. 3. 
b
 SD, standard deviation. 
c
 CV, coefficient of variation. 
d
 ND, not detected. 
e
 Values are numbers of genome copies. 
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FIG. 3. Schema of the location of tissue samples taken from a surgically removed Buruli 
ulcer plaque lesion. The dots show the location of the specimens subjected to IS2404 
TaqMan assay, and their sizes indicate the amounts of M. ulcerans DNA detected. The 
values correspond to the mycobacterial genome copies found in 100 mg of tissue sample. 
C, center of the plaque (diameter, about 1.5 cm); B and B*, firm and slightly elevated area 
of the plaque as identified by the surgeon (about 4 cm); A and A*, excised margins of 
apparently healthy tissue (3 and 1 cm, respectively) (A* faces towards the distal part of the 
forearm); 1, upper layer comprising epidermis and subcutaneous tissue; 2 and 3, deeper 
layers of subcutaneous tissue; 4, flexor tendon.  
                   CHAPTER 5. Development and application of real-time PCR                       97 
 
 
FIG. 4. Amplification products obtained by conventional diagnostic IS2404 PCR with 
DNA extracted from tissue samples taken from a surgically removed Buruli ulcer plaque 
lesion. Lanes 1 to 9, specimens collected from left to right belonging to the layer 1 of Fig. 
3; lanes 10 to 12, specimens collected from left to right belonging to the layer 3 of Fig. 3; 
lanes 13 to 15, specimens collected from left to right belonging to the layer 2 of Fig. 3. The 
lane marked "neg" was loaded with an aliquot from a negative control amplification 
containing no template DNA. The lane marked "+" was loaded with an aliquot from a 
positive control amplification containing M. ulcerans genomic DNA. 
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Abstract 
The distribution of M. ulcerans in Buruli ulcer lesions was analysed by IS2404 real-time 
PCR quantification of M. ulcerans DNA and by semi-quantitative microscopic 
assessment of the number of Acid Fast Bacilli. Mycobacterial burden was compared with 
histopathological changes. Focal distribution of tissue destruction extending into areas 
with high and low mycobacterial burden was a feature in all lesions analysed. Even 
where most of the mycobacteria were washed out of ulcerative lesions, peaks of 
mycobacterial DNA and Acid Fast Bacilli in the necrotic base of the ulcers still marked 
the position of the primary infection focus. Significant amounts of mycobacterial DNA 
and microcolonies were also present in samples from more peripheral regions and 
occasionally in excised margins of macroscopically and histologically healthy appearing 
excised tissue margins. Additional peaks of mycobacterial DNA clearly marked sites 
where satellite lesions were developing. Even when granulomas provided evidence for 
the development of cell-mediated immunity, development of satellite lesions by 
contiguous spreading was not completely prevented. Areas free of mycobacterial DNA 
were found between primary and secondary infection foci and around scarring tissue of 
healing lesions. Results demonstrate that IS2404 real-time PCR analyses represent a 
better tool than the less sensitive and only semi-quantitative microscopic enumeration of 
AFB for studying the dynamics of M. ulcerans infection in situ.   
 
Keywords: M. ulcerans, real-time PCR, histopathology, satellite lesions. 
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Introduction 
Mycobacterium ulcerans infection (Buruli ulcer) is a progressive necrotizing infection of 
the skin and the subcutaneous tissue [1]. The disease has been reported from at least 30 
countries worldwide, mostly in tropical areas, where it mainly affects poor people living 
in rural areas. It can involve all age groups, though children below 15 are predominantly 
affected. Prevalence rates can be as high as 22% as it has been recorded in an endemic 
community in Ghana [2]. The mode of transmission of Buruli ulcer is not entirely clear 
[2], but once M. ulcerans is introduced into the dermis or subcutaneous tissue, it 
proliferates and produces a toxin, designated mycolactone [3]. This polyketide toxin has 
cytopathic activity [4] and causes necrosis of the dermis, panniculus and fascia, usually 
leading to a single, painless, subcutaneous nodule, oedema, or plaque [5]. Fat cells 
enlarge and lose their nuclei and the skin that covers these lesions eventually sloughs off, 
together with the underlying tissues, forming an ulcer with undermined edges [6]. 
Inflammatory cells are scarce in active lesions, but after an unspecified time period, a 
granulomatous response in the dermis and panniculus may be observed, followed by 
healing and scarring [7]. In many cases calcification occurs [7]. M. ulcerans may spread, 
presumably by lymphatic and haematogenous pathways, to distant foci. Occasionally 
metastatic bone lesions arise [8]. 
The currently accepted definitive treatment is the surgical removal of the infected tissue 
including healthy tissue at the peripheral and deep margins [1]. Due to the non-specific 
clinical manifestations of the disease and its indolent course, those affected tend to 
postpone their presentation to the health facilities [9]. This delay can necessitate 
complicated surgical intervention [10]. While early clinical forms can be easily excised 
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and closed by primary suturing, extended lesions require general anaesthesia and skin 
grafting [1].  Currently it is not clear how extensive surgical excision with a curative 
intent should be. It is largely left to the individual judgement of the surgeon to find the 
right balance between an oversized excision and an incomplete removal of the pathogen, 
thus increasing the risk of recurrence. Since recurrence rates between 16% [11] [12] and 
47% [13] have been described, it is important to learn more about the distribution of M. 
ulcerans within lesions.  
 
In this report, we have quantified the distribution of mycobacterial DNA in Buruli ulcer 
lesions using real-time PCR. This method has a detection limit of about 50 copies of the 
targeted sequence IS2404, high PCR efficiency (>90%) and specificity [14]. 
Mycobacterial burden was compared with histopathological changes. Results obtained 
with four selected patients are presented, illustrating contiguous dissemination and 
development of secondary lesions in the proximity of primary lesions. 
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Materials and methods 
 
Clinical specimens 
Patients presenting with ulcerative lesions at the Amasaman Health Centre in the Ga 
district of Ghana were enrolled in this study in July 2003. Clinical diagnosis of Buruli 
ulcer was reconfirmed by IS2404 PCR, microscopic detection of Acid Fast Bacilli (AFB) 
and observation of characteristic histopathological changes. All of the patients who 
enrolled in the study (Table 1) received the standard treatment, comprising wide surgical 
excision of lesions including margins of macroscopically healthy tissue followed by skin 
grafting. The study had no influence on treatment modalities. Ethical approval for 
analysing patient specimens was obtained from the local ethical review board of the 
Noguchi Memorial Institute for Medical Research. Informed consent was obtained from 
the patients or their guardians before enrolment.  
 
The excised tissue was divided into two halves across the centre of the lesion and 
spatially matching samples of each half were taken for histopathological and real-time 
PCR analysis, respectively (Fig. 1).  
 
For PCR sampling, care was taken to avoid cross contamination, by starting sampling 
from the macroscopically healthy looking margins and working towards the centre of the 
lesion, using a separate disposable scalpel to cut each piece. Samples for histopathology 
were stored in 10% formalin, samples for PCR analyses in liquid nitrogen.  
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Real-time PCR analysis  
Extraction of DNA from tissue specimens was done as previously described [14],  
Briefly, the samples were heat inactivated and then subjected to enzymatic and 
mechanical lyses; the DNA was first purified with phenol-chloroform, then precipitated 
with ethanol and finally resuspended in water. The DNA yield was measured with a 
spectrophotometer (GeneQuant) and 50ng of DNA per sample were used for real-time 
PCR. Quantification of M. ulcerans DNA by IS2404 real-time PCR using an ABI Prism 
7700 sequence detection system was done as described [14]. The real-time PCR 
efficiencies were >90% and the coefficients of correlation were from 0.955 to 0.997 
(average: 0.985). Samples were analysed in triplicate and negative controls were included 
in each experiment. All PCR negative samples were positive both in a control PCR 
specific for the human β-actine gene (forward primer: GGACTTCGAGCAAGAGATGG 
reverse primer: AGCACTGTGTTGGCGTACAG) and in IS2404 PCR when spiked with 
50 pg of M. ulcerans DNA, ruling out that negative results were caused by co-
purification of PCR inhibitors or DNA template degradation  
 
Histopathologic examination 
Formalin-fixed strips of excised tissue were cut and sequentially blocked. Precise 
positions from where samples had been taken for PCR analysis from the matching strip 
were marked with ink. Specimens were embedded and processed into paraffin blocks. 
Four micrometer thick sections were cut from each block and stained with Haematoxylin 
and Eosin (H&E) and Ziehl-Neelsen (ZN) according to standard protocols. Each of the 
H&E sections were examined microscopically and semi-quantitatively assessed for the 
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following parameters: inflammation (acute – neutrophils; chronic – plasma cells; 
histiocytes; eosinophils; mild/moderate/dense infiltrate) and for the presence or absence 
of granulomas, dermal and fat necrosis, panniculitis, calcification, neuritis and venulitis 
(inflammation of the wall of the veins).  
Each of the ZN stained sections were double-screened for the presence of AFB, and a 
semi-quantitative logarithmic score of the numbers of AFB detected was recorded (0 : no 
AFB; 100 : a single AFB within the entire section;  101 : up to 10 AFB within the entire 
section; 102 : up to approximately 100 AFB  within the section; 103 : up to approximately 
1000 AFB within a section; 104  : up to approximately 10 000 AFBs, characterised by 
dense clumps of bacilli on ZN stained sections.). 
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Results 
Results obtained with four selected Buruli ulcer patients are presented, illustrating 
contiguous dissemination and development of secondary lesions in the proximity of 
primary lesions. 
Each patient is presented separately, as they had distinct microbiological-
histopathological patterns. 
 
Patient I.  Focal distribution of M. ulcerans in a primary ulcerative lesion. 
Patient I presented with an ulcerated plaque (size of the ulcer: 4cm x 5cm) with necrotic 
slough at the centre, on the dorsal aspect of the left upper arm (Fig. 2).  
 
a. PCR.  The real time PCR analysis showed that the highest mycobacterial DNA burden 
was present in the samples at the base of the ulcer (Fig. 2, samples F, G and H), and 
decreased, generally  with a steep gradient towards the margins.  There were, however, 
small but significant (i.e. PCR value greater than 10) amounts of mycobacterial DNA 
present in the samples from more peripheral and clinically normal parts of the skin (Fig. 
2, samples C and M). 
 
b. Histopathology. There was typical necrosis and inflammation in the centre of the 
lesion (Fig. 2, Fig. 6a, 6b), with irregular clusters of AFB detected in the areas 
corresponding to the highest mycobacterial DNA concentrations (Fig. 6d). The typical 
Buruli necrosis was also seen in zones where there was DNA but no AFB (I).  Occasional 
single AFB were detected in peripheral sections (D and L), where the tissue was inflamed 
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with (Fig. 6c), or without necrosis. AFB were not detected in samples C or M where the 
tissue was histologically normal or nearly so but where PCR identified infection. No 
granulomas were seen in any zone.  
  
Patient II.  Contiguous dissemination and development of a satellite lesion. 
Patient II presented with an ulcerating plaque on the left upper arm measuring 7cm x 5cm 
(Fig. 3). The ulcer, located centrally in the lesion, measured 1.4cm x 1.8cm and had a 
necrotic sloughing base.  
 
a. PCR.  The M. ulcerans DNA distribution had one peak at the centre of the tissue 
adjacent to the ulcer (Fig. 3, sample F), and a second and higher peak of M. ulcerans in 
sample D (plaque, clinically). Significant genome copy numbers were also detected at 
both surgical resection margins (clinically healthy skin). 
 
b. Histopathology. Typical Buruli-type fat necrosis and panniculitis were confluent in the 
central part of the specimen, which incorporated both M. ulcerans PCR peaks (sections D 
to F) (Fig. 6e, 6f).  Typical dermal necrosis was present within sections C and D, with an 
additional focus in section G.  Large numbers of AFBs were detected in the central 
sections (D and E) (Fig. 6g) and low numbers of AFBs were present within the more 
peripheral sections (Fig. 3 samples F, G and H), where fat necrosis and acute 
inflammation was also detected (Fig. 6i). The surgical resection margins were 
histologically normal and no AFB were present, despite the presence of significant 
quantities of DNA. Granulomas were present within the central zones D to G, as well as 
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neuritis (Fig. 6h), venulitis and calcification. No AFB were seen within the inflamed 
nerves. 
Thus the centre of the lesion was an advanced Buruli ulcer, and there was a secondary 
infection focus developing (sample D) as indicated by the peak of mycobacterial DNA. 
Clinically the texture of the tissues was different in this secondary focus.  
  
Patient III.  Absence of mycobacteria in tissue separating two neighbouring lesions. 
Patient III presented with a small ulcerated lesion and a larger non-ulcerated nodule 
located about 3cm apart on the dorsal aspect of the right elbow (Fig. 4). Although the 
ulcer itself was only 1cm in diameter, wide surgical excision was performed to remove 
both lesions “en masse”.  
 
a. PCR. The M. ulcerans DNA distribution had two peaks, a smaller peak associated with 
the ulcerated region and a second, much larger peak, associated with the non-ulcerated 
nodular lesion. The concentration of  M. ulcerans DNA decreased in a very steep gradient 
from the centre of the nodule to the adjacent tissue samples F and D, which both 
contained 1000 fold less DNA than sample E.  In tissue sample G, between the two 
lesions, no M. ulcerans DNA was detected.  
 
b. Histopathology. Typical dermal and fat necrosis was present within sections E (Fig. 6j) 
and F (Fig. 6l), corresponding to the nodular lesion. AFB were found by microscopy only 
in sample E (the nodule). PCR identified DNA in zones which were histologically normal 
and had no AFB (C).  Granulomas were present across
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to H) (Fig. 6k) and beyond, without detectable AFB or DNA in the lateral part (I to K). In 
the central zone (G), AFB were absent, as was mycobacterial DNA, showing that the 
ulcer and the nodule were not part of an active continuous lesion (there were granulomas 
in this part indicating previous infection and damage). Probably the nodule represented a 
new infection focus resulting from previous contiguous spread of mycobacteria.   
   
Patient IV.  Absence of mycobacterial DNA in a healing lesion in proximity to an 
active lesion 
Patient IV presented with two ulcerative lesions, a large ulcer on the medial and a smaller 
one on the anterior aspect of the left thigh. The larger ulcer showed signs of previous 
treatment and was surrounded by scar tissue. The smaller ulcer was located 5cm away 
from the larger ulcer. The excised tissue comprised both ulcers (Fig. 5).  
 
a. PCR. M. ulcerans DNA was detected neither in the healing margin of the larger ulcer 
(sample A) nor in the tissue separating the two lesions (samples B and C). However, M. 
ulcerans DNA was detected at the base of the small ulcer (D and E).  
 
b. Histopathology. In the healing margin of the larger ulcer (A, B, C), there was non-
specific mild dermal inflammation, without dermal necrosis, fat necrosis, AFB, or 
granulomas. Samples D and E, corresponding to the small ulcer, showed typical 
appearances of Buruli ulcer, with dermal and fat necrosis, and large numbers of AFBs 
(Fig. 6m, 6n). The AFB corresponded to the peaks of PCR detected DNA. No granuloma 
formation was found in the healing margin of the large ulcer at the time of sampling.  
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Correlation of PCR, AFB and histopathology  
Tables 2a to 2e correlate PCR-DNA positivity, AFB presence, typical Buruli necrosis and 
granuloma formation in 44 samples from the four cases. 
Across all the lesions, more samples had positive DNA (66%, 29/44) than had AFB 
detected (34%, 15/44), and just 1 sample had AFB without DNA present. All but one of 
the samples with Buruli-type necrosis had DNA detected (94%, 16/17) compared with 
76% (13/17) with AFB seen. In samples without necrosis, mycobacterial DNA was 
identified more often (48%, 13/27) compared with detection of AFB (7%, 2/27). 
Granulomas, considered to be one feature of the healing response in Buruli ulcer [6] were 
associated with DNA in 67% (8/12) and AFB in 42% (5/12) of samples. Calcification of 
necrotic tissue correlated with granuloma formation, consistent with a chronic lesion. 
Conversely, in the pre-granuloma phase, 66% (21/32) had DNA compared with 31% 
(10/32) that had histologically visible AFB.  
The distribution of AFB with respect to necrosis was irregular, with clumps of abundant 
AFB (density = 103 or 104) seen in some necrotic zones, whereas others in the same 
patient’s samples were negative or very low density (Fig 6).  
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Discussion 
This is the first study of Buruli ulcer correlating real-time quantitative PCR with 
histopathology. The use of these two techniques on the same samples produced 
complementary information that gave a clearer picture of M. ulcerans distribution in 
lesions. It provided data on the relationship between mycobacterial burden and associated 
tissue damage, as assessed by histopathological assessment, and contributed to the 
understanding of the pathological processes involved in progression of the disease, 
healing and recurrence.  
 
Mycolactone, secreted by M. ulcerans, has affinity for fatty cells and, by causing 
necrosis, it may create a favourable milieu for mycobacterial proliferation. The 
histological signs of severe tissue damage coincided with high concentrations of 
mycobacterial DNA, and less consistently with high numbers of detectable AFB. In 
addition, there were signs of severe tissue damage in areas where few mycobacteria were 
detected. It is likely that this is due to the diffusion of mycolactone. The preferred 
localisation of M. ulcerans in the subcutaneous fatty tissue [15] was reconfirmed by real-
time PCR analysis of superficial and deeper tissue samples from patients III and IV: the 
deeper portions (mainly fatty tissue) showed up  to 1000 fold higher concentrations of 
mycobacterial DNA than the upper ones (data not shown).  
 
It is generally assumed, from the previous clinico-pathological descriptions of Buruli 
ulcer [16] [17] that the onset of a granulomatous response marks the beginning of 
containment and eventual healing of a M. ulcerans infection [18] [19]. However, results 
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obtained with the specimens from patients II and III demonstrated that new satellite 
lesions can still develop after the onset of a cellular immune response. The relationship of 
cell-mediated immunity, i.e. granuloma formation, to healing in this infection requires 
further research.  Calcification, associated with granuloma formation is presumably 
dystrophic in origin. The significance of the neuritis (seen in patients I and II) is not clear, 
but it is unusual in other dermal inflammation conditions apart from leprosy. No AFB 
were seen in the nerves. 
 
 While IS2404 real-time PCR quantifies the entire load of mycobacterial DNA in a tissue 
block, the less sensitive microscopic enumeration of AFB (estimated detection limit: 
1000 bacilli per ml) only reflects the mycobacterial burden in the individual sections 
examined. Due to the clustered distribution of mycobacteria in microcolonies (Fig 6c, 6d) 
[7] microscopic quantification of AFB was in general less reliable than DNA 
quantification and AFB staining did not reliably demonstrate contiguous spreading. 
Taking the limitations of the microscopic enumeration of AFB into account, an overall 
good correlation between the PCR-based and the microscopic analysis was observed. 
  
The highest quantity of M. ulcerans DNA (i.e. log 5 or more) was found focussed in 
small tissue areas representing new infection foci with necrosis. Even when most of the 
mycobacterial DNA was washed out from ulcerated foci, peaks of DNA in the necrotic 
base of the ulcers still marked the position of the original infection focus, as in patient I.  
Although the vast majority of AFB and mycobacterial DNA remained confined to the 
central infection foci, some lateral spreading, sometimes extending into macroscopically 
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and histologically healthy appearing margins, was observed. In a patient not presented in 
this study, we observed a recurrence at a site, where the healthy appearing tissue 
contained significantly more mycobacterial DNA than in specimens taken from other 
sites (Rondini, unpublished observation).  
 
Care was taken to avoid DNA cross-contamination between samples used for PCR 
analysis. Areas free of mycobacterial DNA were found between primary and secondary 
infection foci and around scarring tissue in proximity to an active mycobacterial DNA 
containing focus, demonstrating that it is possible to avoid carry over of significant 
amounts of DNA.  
 
Surgical treatment of Buruli ulcer entails to the loss of large amounts of tissues. Early 
detection and surgical removal of small lesions prevents many complications and reduces 
costs [10]. Therefore it is particularly important to understand the progression of the 
disease with the goal to minimize the size of the excision, whilst at the same time 
reducing the risk of recurrences. Follow-up of the four patients enrolled in this study 
showed that they did not develop any recurrence during a period of 16 months. The wide 
surgical excision applied at the Amasaman Health Centre appeared to be effective in 
removing both primary infection foci and satellite lesions. This result is in agreement 
with a recent retrospective analysis comparing treatment outcome in two hospitals with 
different surgical treatment procedures for Buruli ulcer [13].  Long term follow-up of 
patients supported the concept that wider surgical excision improves the chance of 
healing of Buruli ulcer.  
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Our results emphasize, that careful macroscopic evaluation of the tissue surrounding 
primary foci is required prior to and during surgery to identify and excise newly 
developing satellite lesions. Application of the molecular approach described here for 
assessing excision margins, combined with long term follow-up of patients, should help 
to improve current guidelines for surgical treatment of Buruli ulcer.  
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Table 1 List of patients enrolled in the study 
 
 
 
Table 2 Correlation of PCR, AFB and histopathology 
 DNA+ DNA- Total 
AFB+ 14 1 15 
AFB- 15 14 29 
Total 29 15 44 
Table 2a 
 
  Buruli necrosis + Buruli necrosis - Total 
AFB+ 13 2 15 
AFB- 4 25 29 
Total 17 27 44 
Patient 
Age Sex Type of lesion Site 
Lenght of 
examined tissue 
I 11 M plaque with ulcer left upper arm, dorsal 15cm 
II 5 F plaque with ulcer left upper arm, ventral 10cm 
III 21 F 
(1) small nodule with 
central ulcer 
(2) large nodule 
(1)right elbow, lateral 
(2) right elbow, dorsal 
12cm 
IV 45 F 
(1) small ulcer 
(2) large ulcer 
(1) left thigh, frontal 
(2) left thigh, lateral 
15cm 
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Table 2b 
 Buruli necrosis + Buruli necrosis - Total 
DNA+ 16 13 29 
DNA- 1 14 15 
Total 17 27 44 
 
Table 2c 
 
 Granuloma + Granuloma- Total 
DNA+ 8 21 29 
DNA- 4 11 15 
Total 12 32 44 
 
Table2d 
 
 Granuloma + Granuloma - Total 
AFB+ 5 10 15 
AFB- 7 22 29 
Total 12 32 44 
 
Table 2e 
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Fig. 1 Schematic view of the sampling method 
1: first half of excised tissue used for histopathology. Sections were taken in 
correspondence with the marked dots 
2: second half of excised tissue used for real time PCR; a-i: samples matching the marked 
dots, where DNA quantification was performed 
t: tissue macroscopically affected 
u: ulcer site 
m: margins macroscopically healthy 
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m 
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N M L K J I H G F E D C B A 
no no no no no yes yes yes yes yes yes no no no fat necrosis 
no no no no no yes yes yes yes yes yes no no no dermal 
necrosis 
no no no no no no no no mild no no no no no eosinophils 
no no no no no mild mild severe moderate mild mild no no no neutrophils 
no no no no mild mild mild moderate moderate no no no no no plasma cells 
no no no mild mild mild mild moderate moderate mild mild mild no no histiocyte 
no no no no no no yes no no no no no no no neuritis 
no no no no no no yes yes no no no no no no venulitis 
no no no no no no no no no no no no no no calcification 
no no no no no no no no no no no no no no granulomas 
no no no no yes yes yes yes yes yes no no no no panniculitis 
0 0 1 0 1 0 102 101 104 101 101 0 0 0 AFB 
N M L K J I H G F E D C B A Tissue 
sample 
Fig. 2 Patient I  
Genome copies corresponding to 50ng extracted DNA 
H, healthy looking tissue P, plaque U, ulcer  
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Fig. 3 Patient II  
Genome copies corresponding to 50ng extracted DNA 
H, healthy looking tissue P, plaque U, ulcer 
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Fig. 4 Patient III 
 
Genome copies corresponding to 50ng extracted DNA 
H, healthy looking tissue N, nodule U, ulcer 
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Fig. 4 Patient III 
 
Genome copies corresponding to 50ng extracted DNA 
H, healthy looking tissue U, ulcer 
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Fig. 6 
a-d Patient I. a sample H: low power image of Buruli ulcer showing extensive Buruli-
type (coagulative) necrosis throughout the mid and deep dermis, with extensive fat 
necrosis of subcuticular adipose tissue. There is a characteristic absence of inflammatory 
cells. b sample G: high power ulceration, with calcification. c sample D: dense clumps of 
AFB visible on H&E stain. d sample H: ZN stain showing dense clumps (10x4) of AFB. 
e-i Patient II. e sample E: Buruli-type necrosis, with calcification and acute 
inflammation. f sample E: high power image of typical Buruli-type necrosis, fat necrosis 
and a moderate neutrophilic infiltration. g sample D: ZN stain showing aggregates of 
AFBs, lining dead fat spaces, and scattered single bacilli. h sample E: neuritis - 
neutrophilic infiltration of nerve associated with oedema and degenerative appearances to 
the nerve. i sample H: Non-specific fat necrosis and acute inflammation  
j-l Patient III. j sample E: high power image of typical Buruli-type necrosis with fat 
necrosis, lacking inflammation. k sample H: very high power of granulomas, with giant 
cells adjacent to dermal scarring (fibrosis). l sample F: venulitis - inflammation of the 
vein wall with oedema and focal fibrinoid necrosis  
m-n Patient IV. m sample E: low power, including fat necrosis, dermal  'Buruli-type' 
necrosis. n sample D:ZN stain showing clumps of  AFBs.   
a b c d 
e f g h 
i l 
m n 
j k 
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Abstract 
A real-time PCR assay was used to measure the amount of Mycobacterium ulcerans DNA in 
the excised lesion of a Buruli ulcer patient. While the heaviest mycobacterial burden was 
found in the centre of the lesion, macroscopically healthy appearing tissue was also partially 
infiltrated. A recrudescence that developed at the edge of the excision was located in an area, 
where the excised healthy margin contained a significant amount of M. ulcerans DNA. These 
results demonstrate that a relatively small number of mycobacteria that have spread into 
healthy appearing tissue can lead to the development of a recrudescence 
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The newly developed real-time PCR assay (IS2404 Taqman) has enabled the quantitative 
detection of Mycobacterium ulcerans DNA in lesions of patients affected by Buruli ulcer 
(BU) (Rondini et al) The application of the method to examine the margins of an excised 
lesion could provide valuable information in order to forecast possible recrudescence. This is 
the first report correlating the development of a recrudescence in a BU patient who underwent 
surgical treatment, with its original mycobacterial burden. Although the lesion had a focal M. 
ulcerans distribution, small numbers of more widespread mycobacteria were sufficient to 
establish a new infection focus at the edge of the previously excised lesion 
 
Case report 
 A 23-year-old man from the Ga district of Ghana presented in November 2002 with an 
ulcerated plaque (23 x 15 cm) on the right forearm (Fig 1) at the Amasaman Health Centre. 
Within the plaque both an ulcer (3 x 2 cm) and - about 4 cm laterally of it - a non-ulcerated 
nodule was observed. After clinical diagnosis of Buruli ulcer, the plaque lesion was surgically 
removed en block with a margin of 2-3 cm (Fig. 2).  
For the analysis of the spreading of M. ulcerans in the lesion, samples were collected along 
the long axis of the excised tissue (Fig. 2) and the concentration of M. ulcerans DNA was 
determined by real-time PCR as described [1]. The risk of cross contamination was 
minimized by taking the samples starting from the macroscopically healthy looking margins 
and working towards the centre of the lesion, using a separate disposable scalpel to cut each 
piece. Twenty-two specimens adjacent to each other were obtained from this strip of tissue. 
Two extra samples (23 and 24 in Fig. 2) were taken from the margin in a region where, based 
on the macroscopic appearance of the tissue, the surgeon had decided to extend the excision 
beyond the originally planned margins (Fig. 2). Laboratory analyses (PCR, culture and 
histopathology) confirmed the clinical diagnosis of BU. Real-time PCR analysis revealed a 
focal distribution of M. ulcerans, with the highest mycobacterial burden at the site of the 
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nodule (sample 14 in Fig. 3). While the M. ulcerans content was >100 fold higher in this 
sample than in any other sample, smaller peaks were also observed at the margins of the ulcer 
(samples 8 and 11). No significant amounts of M. ulcerans DNA were found in some of the 
samples from the healthy appearing margins (samples 1, 2 and 24) while mycobacterial 
spreading had extend to others (samples 22 and 23).  
The patient was subjected to skin grafting after 30 days of hospitalization and discharged in 
good condition 60 days after admission. Seven months after surgery, he presented to the 
Health Centre with a BU recrudescence located at the site where the excised margin contained 
a significant amount of M. ulcerans DNA (sample 23). After excision of the satellite lesion 
and successful skin grafting (Fig. 2), no further recurrence has developed up to now. 
 
Discussion  
M. ulcerans disease, commonly called Buruli ulcer, is a progressive necrotizing infection of 
the skin and the subcutaneous tissue [2]. The mode of transmission of Buruli ulcer is not 
entirely clear, but once M. ulcerans is introduced into the dermis or subcutaneous tissue, it 
proliferates and produces a toxin, known as mycolactone [3]. This polyketide toxin has 
cytopathic activity [4] and causes necrosis of the dermis, panniculus, and fascia, usually 
leading to painless manifestations like subcutaneous nodules, ulcers, oedema, or plaques. 
Focal distribution of mycobacteria with tissue destruction extending into areas with low 
mycobacterial burden is a common feature of Buruli ulcer lesions. Additional peaks of 
mycobacterial DNA mark sites where satellite lesions in the vicinity of the primary focus are 
developing (Rondini et al., submitted). M. ulcerans may also spread, presumably by 
lymphatic and haematogenous pathways, to distant locations, where metastatic skin and 
occasionally bone lesions arise [5]. The currently accepted definitive treatment of Buruli ulcer 
is the surgical removal of the infected tissue [6]. Due to the frequent delay between the first 
appearance of the disease and the presentation to the health facilities, patients often 
                         CHAPTER 7. Prediction of M. ulcerans recrudescence                                134 
necessitate extended surgical interventions and long periods of hospitalization. Recrudescence 
after surgery has been observed in up to 47% of cases [7]. 
In the Buruli ulcer lesion described in this report, the highest mycobacterial load was detected 
at the site of a nodule, which probably represented a satellite infection focus. Most of the 
mycobacteria were obviously washed out from the primary focus, the neighbouring ulcer. 
Small, but significant amounts of mycobacterial DNA in the excised margins of healthy 
appearing tissue demonstrate that even an excision with wide margins does not always ensure 
that the entire mycobacterial burden is removed. Development of the recrudescence in the 
vicinity of the infected margin indicates that even small numbers of mycobacteria missed by 
surgical treatment can cause a relapse. Even when granulomas provide evidence for the 
development of cell-mediated immunity, development of satellite lesions by contiguous 
spreading is not completely prevented (Rondini et al., submitted). The immune status of a 
patient may, however, determine the mycobacterial load that can still be successfully 
contained. As soon as a microcolony containing a critical number of M. ulcerans cells has 
developed by focal bacterial multiplication, a cloud of mycolactone may cause a local 
impairment to the cellular immune system.  
Traditionally drug therapy on its own has been considered ineffective for treatment of Buruli 
ulcer. Based on recent data, WHO treatment guidelines now recommend to combine surgery 
with a combination of anti-mycobacterial drugs [8]. Combined with conservative surgery 
adjunct antibiotic treatment may impair development of satellite lesions from small numbers 
of M. ulcerans bacteria. It remains to be demonstrated in formal clinical trials, to what extent 
the adjunct antibiotic treatment improves the outcome for patients. Quantification of M. 
ulcerans DNA by real-time PCR can provide insight into the dynamics of M. ulcerans 
infection and is a valuable tool to monitor effects of adjunct antibiotic treatment on 
mycobacterial spreading.  
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Fig.1 
(a) BU patient presenting an ulcerated plaque on the right  
forearm (before surgery – Nov. 2002) 
(b) Extension of the skin-graft due to recurrence (R) 
(July, 2003) 
 
 
R 
b 
a 
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Fig.2 Surgically excised affected tissue 
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Fig. 3 Real-time PCR quantification of mycobacterial genome copies corresponding to 50ng 
extracted DNA 
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Summary: 
 
Mycobacterium ulcerans infection causes a skin disease known as Buruli ulcer (BU), a 
disorder manifested usually as a solitary and painless nodule or papule that progresses 
to massive necrotizing destruction and cutaneous ulceration. When healing occurs, it 
often results in disabling deformities. Buruli ulcer is considered the third most common 
mycobacterial disease in immunocompetent people, after tuberculosis and leprosy. 
Although the emergence of Buruli ulcer in Western African countries over the past 
decade has been dramatic, it has been scarcely reported in industrialised countries.  
 
We report an HIV-positive Equatorial Guinean patient presenting aggressive and 
multifocal BU associated with an underlying destructive osteomyelitis, in which only an 
aggressive surgical approach yielded to a resolution of the disease.  In a global world, 
with increasing migratory population fluxes, an increased awareness to dermatologists 
regarding the clinical, histopathological and microbiological features of BU is important 
in order to avoid significant delays in diagnosis and treatment. 
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Case report 
A 27-year-old woman was referred to our Department for assessment of chronic ulcers 
on her legs. Five years earlier, in 1998, while living in a rural area on the border 
between Equatorial Guinea and Cameroon, she had noticed a painless nodule on her 
right shoulder that became ulcerated. The lesion was surgically excised in 2000 in 
Malabo. In 1999, while living in Malabo, a non endemic BU area, new ulcerated lesions 
had appeared on her left leg. In April 2003, she noticed new painless ulcerations on the 
inner aspect of her right leg and she travelled to Spain seeking a diagnosis and 
treatment. Past medical history revealed only several intestinal parasitism episodes.  
 
Physical examination revealed destructive scarring changes on the left leg, severe 
ankylosis of the knee and several large ulcerations with granulation-like tissue changes 
(fig. 1a). On the right leg, a cutaneous ulcer, 3cm in diameter, was observed and a non-
tender subcutaneous nodule was also palpated (fig. 1a). 
 
A radiological survey disclosed severe bone destruction of the left foot and bone 
erosions on the left tibia, which were confirmed by a computed tomography (fig.1b). A 
chest x-ray film and an abdominal ultrasonography were normal.  
 
Laboratory studies only disclosed a normocytic anaemia (haemoglobin levels: 9.4 g/dl). 
She had positive anti-HIV antibodies detected by Microparticle Enzyme Immunoarray 
(MEIA; Abbott Laboratories) and confirmed by an Inno LiPA assay (Innogenetics). She 
had a viral load of 48.500 copies, a CD4 count of 322/mm3 and a CD4/CD8 ratio: 0.38 
(normal 0.6-2.8).  
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Several skin biopsies were taken from ulcers on both legs. A dermal and subcutaneous 
granulomatous inflammatory infiltrate, extensive fat necrosis, and calcification foci 
were observed (fig. 2a). Specific stains for microorganisms (PAS, Giemsa, Gram and 
Ziehl-Neelsen) were negative. A biopsy from the right leg nodule disclosed in addition 
to the aforementioned changes, several clusters of acid-fast resistant bacilli (positive 
Ziehl-Neelsen stain)(fig. 2b). The specific M. ulcerans IS2404 PCR amplification was 
performed after DNA extraction from all the paraffin-embedded biopsies. In all the 
samples the M. ulcerans DNA target was detected. 
 
Wide-spectrum antibiotics and antiretrovirals including lopinavir/ritonavir, didanosine 
and tenofovir were prescribed. Amputation of the left leg above the knee was 
performed. Both lesions on the right leg were also excised, and full-thickness skin grafts 
were placed. No further relapses have been detected after a 6-monthly follow-up. 
 
 
Buruli ulcer (BU), caused by M. ulcerans, is becoming an emerging infectious disease 
with an impact soon to surpass that of leprosy. Hundreds of cases in well-circumscribed 
foci have been described in Western Africa, establishing a broad endemic area in 
equatorial regions. 
 
Although its mode of transmission is unknown, it is considered that M. ulcerans is 
acquired from the natural environment, after penetrating injuries in the exposed parts of 
the body. Recently, some authors have suggested that some aquatic insects can also 
transmit the disease.1 
 
BU frequently involves legs and arms of young people living in rural areas with limited 
access to health care. The incubation period varies from 2 weeks to 3 years, although it 
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is usually shorter than three months. A firm, non-tender nodule is usually the first 
manifestation of the disease in African patients, which evolves to a painless ulcer with 
undermined edges. Ulceration can be extensive and disfiguring, often affecting 50% or 
more of a limb. Although necrosis rarely penetrates beyond the fascia to underlying 
muscle, an increase in the incidence of osteomyelitis has recently been reported.2 The 
lesions tend to heal after months or years, leading to scarring, ankylosis, and 
contractures. The absence of a host-derived inflammatory response is a characteristic 
feature. 
 
BU has occasionally been observed in volunteers or journalists3 who have travelled to 
Africa, as well as in immigrants who contracted the disease while living in endemic 
areas.4 Most patients who were treated in non-endemic areas were seeking a 
diagnosis.5,6 
 
From 4% to 15% of patients may develop multifocal BU. In such instances, M. ulcerans 
may spread by lymphatic, and haematogenous pathways to distant foci, usually the skin 
and bone.7 Reinfection or autoinoculation mechanisms have also been postulated.8  
Reinfection seems improbable in our patient as new lesions appeared while living in a 
non-endemic area.  
 
Unlike tuberculosis, the emergence of BU has not been linked with co-infection by 
HIV. Although HIV is not considered a risk factor, some authors have suggested that an 
immunological impairment such as HIV infection may facilitate multifocal aggressive 
forms of the disease.8,9 
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The diagnosis can easily be achieved in endemic areas when characteristic clinical and 
epidemiological features are met. Cultures may be negative due to critical 
decontamination treatments. Similarly, as the Ziehl Neelsen staining has a low 
sensitivity, a negative result does not rule out the diagnosis of BU. PCR techniques may 
be especially useful to confirm the diagnosis.10The differential diagnosis should include 
several disorders clinically characterized by persistent nodules or chronic destructive 
cutaneous ulcers such as pyogenic cellulitis, tropical ulcer, leishmaniasis, mycetoma 
and tuberculosis. An early, aggressive surgical approach is the only effective treatment 
at present. 
 
The diagnosis of BU should be considered when dealing with a chronic skin ulcer in a 
patient who has recently lived in or travelled to an endemic region. Surgical treatment 
should not be delayed, as left untreated this infection can lead to extensive sequelae.1 
Considering increasing immigration and international travelling, a future rise in the 
number of cases of  BU observed in industrialized countries seems to be predictable. 
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Figure 1a  
Destructive scarring changes and several large ulcerations with granulation-like tissue 
changes on the left leg. On the right leg, a cutaneous ulcer, 3cm in diameter, with 
slightly undermined edges is observed 
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Fig. 1b  
Computed tomography showing one erosion on the left tibia. 
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Figure 2 (a) Granulomatous inflammatory infiltrate, fat necrosis, and calcification foci 
(hematoxylin and eosin, x60). (b) Multiple bacilli are demonstrated by a positive Ziehl 
Neelsen stain (x60).  
a
b 
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9.1 Implications of the main findings and suggestions for further research 
 
After the first International Conference on Buruli ulcer Control and Research in 1998, 
research on this neglected disease has been intensified and new important features have been 
discovered. However, there are still many unsolved questions that need to be clarified, mainly 
in the fields of epidemiology and transmission, treatment and prevention, pathology and 
diagnosis.  
Within the framework of the present thesis, the development of new molecular tools to study 
M. ulcerans allowed investigating several aspects of the disease. The most important findings 
contributed to our knowledge on M. ulcerans genetic variation, epidemiology & transmission 
and disease progression. 
 
9.1.1. Genetic variation in M. ulcerans 
The studies on M. ulcerans diversity performed with different typing techniques have all 
revealed a clonal population structure within specific geographical regions1-6 and a low level 
of genetic variation, typical of mycobacterial species, as observed also for M. tuberculosis. 
More in detail, MIRU and MLST analysis evidenced an extremely homogeneous genomic 
architecture among isolates from the same region, and an overall low rate of single nucleotide 
polymorphism7,8. Although several studies have been undertaken, the basis of M. ulcerans 
genetic diversification has not been elucidated yet.  
The major contribution of the present work in this field is represented by the description of 
insertional/deletional polymorphism and its implications for functional genomics (Chapter 3).  
M. ulcerans belongs to the category of non tuberculous mycobacteria, where many other 
environmental species are grouped as well. This is a very heterogeneous group including non 
pathogenic species (saprophytes like M. smegmatis or M. vaccae) and opportunistic bacteria 
(facultative pathogens like M. marinum, M. chelonae and M. fortuitum). A phylogenetic 
analysis on 16s rRNA has suggested a very close genetic relationship between M. ulcerans 
and M. marinum, indicating a divergence of the species dated less than 100 000 years ago. M. 
ulcerans is thus of relatively recent evolutionary origin9,10.  The discovery of the virulence 
plasmid pMUM001, absent in M. marinum, further enlightened the basis of M. ulcerans 
specific pathology11. The source of this 174 kb plasmid is not clear, but M. ulcerans might 
have acquired it by lateral gene transfer from other microbial communities (probably among 
the actinomycetes), conferring the capability of mycolactone secretion. Whether M. ulcerans 
existed in the environment in a non pathogenic form before the acquisition of the virulence 
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plasmid it is not known, although it is clear that the production of a functional toxin is needed 
for growth in insects’ salivary glands and in human tissues. Recent data have also shown that 
the inherent instability of the plasmid can generate various mycolactone forms and that 
insertion-deletion events can occur among the highly homologous modules of the plasmid12. 
After this first report on M. ulcerans, showing the importance of lateral gene transfer to 
acquire virulence, a more dynamic scenario, although limited at the plasmid level, was 
proposed.  
The results we obtained through comparative genomic hybridizations of different M. ulcerans 
isolates, using a new plasmid-based microarray technology, demonstrated that large sequence 
polymorphisms, mediated by insertion-deletion events, may represent the dominating driving 
force of genetic variation. This is a common feature within the mycobacterium genus, and 
more specifically within the M. tuberculosis complex, where the progressive deletions of 14 
regions of difference has mediated the sub-branching, from a common M. tuberculosis 
ancestor, of all the other members till the highly attenuated BCG Pasteur13. 
 
 
 
 
 
Figure 1. Scheme of the proposed evolutionary pathway of the tubercle bacilli illustrating 
successive loss of DNA (Source: Brosch et al, PNAS 2002)  
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The M. ulcerans genome is substantially smaller than the M. marinum genome; on top of that 
we could map deletions of considerable size (up to 50 kb, which already represents the 
genetic variation occurring between M. bovis and M. tuberculosis). Preliminary results from 
the Buruli ulcer genome project, has confirmed a certain level of genomic decay, with the 
presence of insertion sequences covering 5% of the whole genome and many pseudogenes14. 
Not surprisingly, among the deleted CDS that we were able to identify, insertion sequences 
and pseudogenes were deleted in excess, with the last ones alone accounting for the 22% of 
the all deleted CDS. Together with these disposable elements, also genes involved in 
detoxification were overrepresented among the deletions, showing that their importance is 
limited for the extracellular M. ulcerans bacilli. According to the pattern of deletions 
observed, we could postulate that M. ulcerans might be facing an adaptation phase from an 
environmental mycobacterium to an organism which is getting accustomed to a more stable 
environment. The well documented genomic downsizing that already occurred in M. leprae, 
with a genome comprising only 3.27 Mb and 1600 genes, is an example of reductive 
evolution to a minimal gene-set required for a pathogenic mycobacterium15.  At the moment it 
is not clear whether M. ulcerans is adapting to restrict its multiplication in a mammalian host, 
or in another unidentified ecological niche. 
The publication of the fully annotated M. ulcerans genome will open new possibilities to 
perform direct comparisons among different mycobacteria, in order to identify genetic 
fingerprinting methods for epidemiological investigations, and new antigens for both 
diagnostic and vaccination studies.  
 
9.1.2 Epidemiology and transmission 
The epidemiology of M. ulcerans has not been fully clarified yet, and due to the patchy 
distribution of the cases and the considerable underreporting, it is hard to draw an overall 
picture of its prevalence. It is in sub-Saharan Africa that the main burden of the disease falls, 
where, after the first reports of the Uganda Buruli Group in the ‘60s16, new endemic foci are 
being discovered17-23. One of the contributions of the present work lies in the rediscovery of a 
hidden pocket of Buruli transmission in the Nyong River basin in Cameroon (Chapter 4). This 
endemic area, after its first description in 1969, has been ignored for about 30 years, till when 
our cross-sectional survey identified more than 430 Buruli ulcer cases urging health care 
interventions. The case of Cameroon can be regarded as a successful example of the impact 
that such studies may have on the establishment of beneficial interventions for the affected 
populations: the obtained results led to the beginning of a surgical treatment program 
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conducted by Aide aux Lepreux Emaus Suisse (ALES) and by Médicins Sans Frontières who 
have treated several hundreds patients so far. Beyond the usefulness of these emergency 
initiatives, it is important to draw attention also on the need to implement long-term strategies 
like control programs, upgrading surgery facilities, promoting health education, training the 
local staff to detect early cases, and providing rehabilitation for those already deformed by the 
disease. 
 
Understanding the mode of transmission would constitute the best way to prevent (if 
possible), or to control the infection.  But, beyond the empirical observation that the proximity 
to swamps and wetlands is often associated with Buruli ulcer insurgence, the exact mode of 
transmission remains unknown.  
Hayman, studying M. ulcerans epidemiology in Australia, postulated such association24, 
which was further supported by several independent lines of evidence, like the detection of 
bacilli in water samples during an outbreak25, their isolation from aquatic insects collected in 
an endemic region of Côte d’Ivoire26, and the finding that aquatic snails might act as passive 
hosts27. These results could implicate that the source of infection is water-related and its 
proximity might increase the risk of getting infected. The results obtained in Cameroon 
confirmed this hypothesis: the villages closer to the slow flowing Nyong river presented a 
higher prevalence than the others (Chapter 4). To further investigate how exactly the 
mycobacteria come into contact with the human host, several possibilities have been 
postulated: (1) by aerosol spray of contaminated water sources, (2) by water-related activities 
(like fishing, bathing, washing clothes, or fetching water), or (3) by an animal reservoir 
present in the endemic areas. There are convincing data for all the above cited possibilities. 
On the contrary, person to person transmission does not seem to play an important role. 
(1) The first possibility is sustained by the results obtained from the Buruli ulcer outbreak that 
occurred on Phillip Island between 1992 and 199525. This sudden increase of Buruli cases 
could be associated with an irrigation system of a golf-course, which had the capacity to 
aerosolize the bacteria over a wide area. Interestingly, when the swamp where the water used 
for irrigation came from, was reclaimed, also the cases ceased to appear. 
(2) To support the second hypothesis, a recent case-control study performed in Ghana28 
reported a significant greater risk of developing Buruli ulcer for people who swim in the river 
on a regular base. Although it was not possible to exclude whether the transmission would 
occur in the river itself, it seemed plausible that the contact with riverbanks vegetation, which 
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was found to stimulate the growth and biofilm formation of M. ulcerans29 and where insects 
live26, could constitute a major risk factor.  
(3) The third possible pathway of transmission is sustained by several data on the detection of 
M. ulcerans in various animals, and by the fact that it was possible to induce Buruli ulcer 
lesions in mice, after the bites of water bugs of the Naucoridae genus. Up to now, however, 
the contribution of this other potential transmission mode has not been defined. 
It would be interesting to investigate, among the affected people documented in Cameroon, if 
an association between behaviour and disease can be found, and which are the most likely 
sources of Buruli ulcer for the local population. A more ecological type of approach should be 
undertaken to monitor different water insects that might behave as vectors of M. ulcerans, in 
order to understand whether their biting behaviour could be directly associated with infection, 
or if they are part of a more complex transmission chain.  
Another suggestion for future studies could be the application of our newly developed real-
time PCR assay (Chapter 5) to monitor environmental samples from the Buruli ulcer endemic 
area, with the goal to discover its ecological niche. Conventional PCR has shown M. ulcerans 
presence in many different organisms and environmental samples, but the type of results 
obtained so far were only qualitative, but not quantitative, and thus did not provide 
information about preferential accumulation of bacteria in particular type of samples. By 
applying real-time PCR on water bugs, snails, fish, or riverbank vegetation, it might be 
possible, on one hand to follow the chain that brings it into contact with humans, on the other 
hand to identify environmental reservoirs and risk factors. In the literature there are already 
examples of such studies, like the detection of Vibrio vulnificus in seawater and oyster 
samples30, or the monitoring of the fate of Escherichia coli O157:H7 in irrigation water on 
soils and plants31. 
These types of studies may be rendered more complicated by the recent findings that IS2404, 
used as target to perform conventional and real-time PCR, is not unique in M. ulcerans, as 
once believed, but it has been found in other mycobacterial isolates32-34. The real risk of 
misinterpretation of PCR data provoked by these newly discovered mycobacteria still needs to 
be assessed. 
 
9.1.3 Disease progression  
Much of the M. ulcerans pathology has been attributed to the secretion of the mycolactone 
toxin, whose injection in guinea pigs’ limbs mimicked typical Buruli ulcer lesions35. In human 
lesions it is possible to detect scattered large clumps of AFB mycobacteria (most likely 
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secreting mycolactone) in the centres of the ulcers, together with severe histopathological 
changes like fat necrosis, infarction of blood vessels, neural destruction and calcification. 
Interestingly, lesions especially in their late stages present little or no inflammatory response, 
with virtually no host cellular response36,37, while, during the healing phase, the lesions 
account for an increased number of immune cells and far less AFB38,39. The subcutaneous 
fatty tissue, with its affinity for M. ulcerans (which has a very hydrophobic cell surface) and 
mycolactone, seems to constitute the primary site of bacterial multiplication, from where the 
mycobacteria are able to spread further. Spreading to distant sites seems to be relatively rare, 
since recurrences usually occur at the sites of excision, most probably due to incomplete 
mycobacterial removal. It seems likely that the initial accumulation of the mycolactone 
guarantees a favourable milieu for more rapid mycobacterial proliferation40. In some patients, 
however, development of multiple “metastatic” lesions, speaks for haematogenous spreading.  
Since the only quantitative detection tool available so far has been the AFB enumeration –a 
technique lacking sensitivity and specificity- it was not yet possible to evaluate the spreading 
of the bacteria within a lesion. For this reason, one of the most important contributions of this 
PhD work was the development of a much more sensitive real-time PCR assay that allowed 
quantifying the mycobacterial burden within excised tissue samples (Chapter 5). The most 
interesting findings, resulting from the application of such method combined with 
histopathology, enabled a deepening of the current knowledge on M. ulcerans distribution and 
spreading, and on the relationship between tissue damage and mycobacterial presence 
(Chapter 6). Furthermore, we could use the newly developed technique to evaluate the 
effectiveness of the actual surgical procedure, and the risk of getting a recrudescence at the 
excision site (Chapter 6-7). 
From the results obtained it was possible to confirm that the initial infection focus locates 
within the subcutaneous fatty tissue. At the moment it is not clear what the dominating 
infection route is and whether the primary inoculation can reach the subcutaneous fatty tissue 
directly (i.e. via wound or insect bite). Probably supported by the local accumulation of 
mycolactone, the mycobacteria proliferate and invade surrounding areas: the fact that we 
noticed signs of severe tissue necrosis, in areas with very low mycobacteria levels, gives an 
indication for the “preparatory” role that the toxin may have before the establishment of new 
mycobacterial foci. Another interesting feature is the development of the so called “satellite 
lesions” in the neighbouring regions of a primary ulceration. The lack of mycobacteria and of 
histopathological changes in intervening samples between the primary and the satellite lesion, 
showed that these contiguous dissemination events are not merely the result of a 
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homogeneous horizontal propagation, rather they represent newly established foci of 
“migrating” mycobacteria. The data obtained indicate that even a granulomatuous response 
mounted in the primary ulcerated focus of infection, as an attempt to contain the bacteria, is 
not sufficient to prevent the escape and the development of a new focus that constitutes a 
newly formed nodule. The most probable way of spreading of such escaped mycobacteria 
could be through the lymphatics, considering both the temperature barrier of 37 degrees and 
the observed necrosis of the blood vessels.  
A better understanding of the dynamics of M. ulcerans spreading will be useful to promote 
guidelines for the surgeons performing excision operations, which represent, at the moment, 
the gold standard of Buruli ulcer treatment. The experience and, more recently, additional 
comparative studies41 have shown that the wider the excision, the least the risk of getting a 
recrudescence, although it might mean a more complicated intervention, more skin to graft 
and higher risk of secondary bacterial infection. However, finding a balance is not easy, 
considering also that there is probably a certain mycobacterial threshold the immune system 
can cope with. The quantification of such threshold is not straightforward and is probably 
dependent on host-related factors.  
In one case we could demonstrate that the presence of small but significant levels of 
mycobacteria at one side of the healthy margin of the excised tissue was enough to provoke a 
recurrence at the same site, reinforcing the concept that in each surgery wide healthy 
appearing margins should be included (Chapter 7).  
The use of real-time PCR to predict recurrences is already used in tumour therapy, where the 
detection of melanoma micrometastases in sentinel lymph nodes is critical for the prognosis 
of the patients42. The application of the M. ulcerans real-time PCR to a larger number of cases 
thoroughly documented and scrupulously followed up, could enlighten possible associations 
between clinical appearance and mycobacterial presence according to the particular stage of 
the disease, in order to predict what type of intervention would be best suited for the patient to 
minimize the risk of relapses. 
 
Real-time PCR approaches have been also used to detect and quantify M. tuberculosis43 and 
M. leprae44 in tissue samples, and it was proposed to use them to monitor treatment efficacy. 
Treatment failures with M. tuberculosis, due to the spreading of drug-resistant strains, make 
mandatory an early evaluation of the efficacy of the drug regimen used, considering also the 
long duration of the complete therapy and the overall costs on the health system. A major 
draw back of real-time PCR assays is represented by the measurement of “total mycobacterial 
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DNA content”, meaning “viable counts” plus dead bacilli, which could hamper an effective 
monitoring of the decline of bacilli after drug treatment45. This type of problem may also arise 
if treatment efficacy is monitored in Buruli ulcer. To overcome such difficulty it would be 
advantageous to develop a real-time reverse transcription-PCR system for M. ulcerans, 
considering that mRNA disappearance would be a better indicator to monitor chemotherapy 
efficacy46.  
 
An important issue in M. tuberculosis infection is the fact that even a prolonged drug regimen 
does not guarantee sterilization. The mycobacteria may persist in the host according to two 
different models: the “static equilibrium”, in which bacterial replication is slow or absent, or 
the “dynamic equilibrium”, in which continued replication is balanced by an equally rapid 
rate of killing by the host immune response47. In this second situation, there would be an 
accumulation of dead bacteria, whose number would be continually growing compared with 
the number of live ones. Recent results supported the first model, with the existence of a static 
equilibrium between host and pathogen48. The existence of persistent forms of M. ulcerans 
has not been proven yet, but anecdotal cases indicate that some patients develop new Buruli 
lesions at new sites after prolonged time intervals after excision interventions. This 
phenomenon may be related to an inherently higher host susceptibility to reinfection, but it 
could also be caused by metastatic spreading of the same infecting bacterial strain, which 
might be able to persist in the patient for long periods of time and provoke the formation of 
new lesions at distant sites.  
The post-operation re-insurgence of Buruli ulcer lesions, which we could monitor in an 
immunocompromised patient after his migration to a non endemic region (Chapter 8), led us 
to speculate whether M. ulcerans reactivation instead of reinfection has occurred. The 
physical distance of the patient from the original endemic region and the time span 
interposing between the primary Buruli manifestations and the recurrent forms was such to 
postulate eventual persistence of M. ulcerans in an immunocompromised individual. This 
would be a completely new field to explore, but at the moment, the lack of animal models 
resembling this condition hampers those studies aimed to the discovery of eventual M. 
ulcerans persistent forms, and to the identification of their preferential location.  
As initial approach to study M. ulcerans persistence, it would be interesting to start 
investigating the contribution of reactivation versus reinfection in patients presenting Buruli 
ulcer recurrent forms. To allow such differentiation, fine typing tools able to discriminate 
among isolates from the same endemic district would be needed. For example, when such 
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tools became available for M. tuberculosis genotyping, it became clearer that the ratio of 
reinfection versus reactivation is proportional to the transmission rates of the particular 
region: in high incidence areas the contribution of reinfection is more consistent that 
reactivation and vice versa49,50.  As already described, the microarray technique, permitting 
whole genome analysis, would have the potential to constitute such tool (Chapter 3) and an 
upscaled version of the already developed prototype microarray could be employed to 
characterize strains isolated from relapsing patients. 
 
9.2 Conclusions 
In this work the development of new molecular genetic tools to investigate M. ulcerans 
infection is described. The application of such methods contributed to our understanding of 
the genetic diversity and pathology of M. ulcerans. Based on the findings generated during 
these studies, the following conclusions can be drawn. 
 
1. A microarray-based comparative analysis of the genomes of M. ulcerans isolates 
confirmed a remarkable lack of genetic diversity and a clonal population structure 
within given geographical regions. As for M. tuberculosis, large sequence 
polymorphism appears to constitute the most important source of genetic variation for 
M. ulcerans. The deletions discovered among the tested 30 M. ulcerans strains 
revealed a total of 241 genes missing, including all major functional categories. Genes 
predicted to encode metabolic, information pathways and cell wall proteins were 
underrepresented, while pseudogenes, (accounting for the 22% of all the deletions) 
insertion sequences, unique hypothetical proteins and genes involved in detoxification 
and adaptation were overrepresented. The potential of the microarray approach to 
detect deletions may represent a suitable basis for the development of a genotyping 
system required for micro-epidemiological studies. 
 
2. A survey performed in Cameroon led to the rediscovery of a Buruli ulcer focus after 
 more than 30 years of no reports, urging control program implementation. This study 
 also reconfirmed the relationship between insurgence of Buruli ulcer and presence of 
 water: the villages closer to the slow flowing Nyong river presented a higher 
 prevalence than those located further away. IS2404 PCR represented the most 
 sensitive approach to reconfirm clinical diagnosis.  
 
                             CHAPTER 9. General Discussion and Conclusions                                 160 
3. The development of a real-time PCR method for the quantification of M. ulcerans 
DNA (IS2404  TaqMan) represented a new highly specific research tool, with a ten 
times higher sensitivity than the conventional PCR-based diagnostic test. We could 
demonstrate that its application to samples derived from Buruli ulcer lesions allowed a 
quantitative assessment of the dissemination of the mycobacteria. The IS2404 TaqMan 
assay therefore represents a useful tool for both diagnosis and research into the 
pathology and mode of transmission of Buruli ulcer. 
 
4. The combination of histopathology and IS2404 real-time PCR on Buruli ulcer tissue 
samples allowed a direct comparison between mycobacterial burden and damage 
provoked by M. ulcerans infection. Significant amounts of mycobacterial DNA and 
microcolonies were also present in samples from more peripheral regions and 
occasionally in excised margins of macroscopically and histologically healthy 
appearing tissue. Additional peaks of mycobacterial DNA clearly marked sites where 
satellite lesions were developing. Even when granulomas provided evidence for the 
development of cell-mediated immunity, development of satellite lesions by 
contiguous spreading was not completely prevented. IS2404 real-time PCR analyses 
represented a better tool than the less sensitive and only semi-quantitative microscopic 
enumeration of AFB for studying the dynamics of M. ulcerans infection in situ.   
 
5. The real-time PCR assay allowed the identification of a site in a Buruli ulcer patient 
prone to develop a recurrence after surgery. The recrudescence developed in fact at the 
edge of the excision, in an area where the excised healthy margin contained a 
significant amount of M. ulcerans DNA. This study demonstrated that even a 
relatively small number of mycobacteria that have spread into healthy appearing tissue 
can lead to the development of a recrudescence. 
 
6. The development of a new Buruli ulcer lesion was documented in a HIV+ patient, 
who moved to a non Buruli endemic region. This case represented an example of  M. 
ulcerans reactivation instead of reinfection, due to the physical distance of the patient 
from the endemic region and the time span interposing between the primary Buruli 
manifestations and the recurrent forms.   
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